Document:

iex4-1.htm

SHAREHOLDERS’ AGREEMENT

 

Shareholders’ Agreement, dated as of December 1, 2010 (this “Agreement”), by and among Insmed Incorporated, a Virginia corporation (“Insmed”), and the Persons listed on Schedule I attached hereto (each, a “Shareholder” and collectively the “Shareholders”).

 

WHEREAS, on the date of this Agreement, Insmed,  Transave, Inc., a Delaware corporation (“Transave”) and certain other parties entered into an Agreement and Plan of Merger (as amended or modified from time to time, the “Merger Agreement”) pursuant to which River Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Insmed (“Merger Sub”), will merge with and into Transave after which Transave will continue as the surviving entity, and immediately thereafter and as part of an integrated plan, Transave will merge with and into Transave, LLC, a Delaware limited liability company and a wholly owned subsidiary of Insmed, with Transave, LLC as the surviving entity (the “Merger”);

 

WHEREAS, at the Effective Time of the merger of Merger Sub with and into Transave, certain capital stock of the Transave that is owned by the stockholders of Transave shall be converted into the right to receive shares of Insmed Common Stock (as defined below) and Insmed Preferred Stock (as defined below), as set forth in the Merger Agreement; and

 

WHEREAS, in connection with the execution of the Merger Agreement and the contemplated consummation of the transactions contemplated therein, Insmed and the Shareholders agree to enter into this Agreement as of the date hereof.

 

NOW, THEREFORE, in consideration of the foregoing and the agreements contained in this Agreement, and intending to be legally bound by this Agreement, Insmed and the Shareholders agree as follows:

 

 

1. Definitions.  Capitalized terms used and not otherwise defined in this Agreement that are defined in the Merger Agreement shall have the meanings given such terms in the Merger Agreement.  As used in this Agreement, the following terms shall have the respective meanings set forth in this Section 1:

 

 

“Affiliate” means, with respect to a Person, any other Person directly or indirectly controlling or controlled by or under direct or indirect common control with such specified Person.  For purposes of this definition, “control” (including, with correlative meanings, the terms “controlling,” “controlled by” and “under common control with”), as used with respect to a Person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person, whether through the ownership of voting securities, by agreement or otherwise.  Notwithstanding the foregoing, solely with respect to Beacon Bioventures Limited Partnership (formerly known as Fidelity Biosciences Limited Partnership) and Beacon Bioventures Principals Limited Partnership (formerly known as Fidelity Biosciences Principals Limited Partnership) (collectively, the “Beacon Bioventures Funds”), for purposes of Sections 3.3, 3.4, 4, 5, and 8, an "Affiliate" shall be deemed to only include the general partner of the Beacon Bioventures Funds and their officers. 

“Articles of Amendment” means the Articles of Amendment, dated December 1, 2010 to Articles of Incorporation of Insmed setting forth the terms of the Insmed Preferred Stock.

“Board” shall mean the Board of Directors of Insmed.

 

“Bylaws” shall mean the Amended and Restated Bylaws of Insmed in effect on the date hereof, as they may be amended or restated from time to time.

 

“Competitor” shall mean any Person who engages in the business of inhaled treatments for lung infections or that engages in any other business which is in competition with or substantially similar to the business of Insmed (as of a Transfer date) in any line of business in which Insmed is engaged; provided, however, that a Person shall not be deemed a Competitor if less than two percent (2%) of its consolidated annual revenue is generated from such businesses described above.

 

“Insmed Common Stock” means shares of common stock, par value $0.01 per share, of Insmed.

 

“Insmed Preferred Stock” means the shares of Series B Conditional Convertible Preferred Stock, par value $0.01 per share, of Insmed with such terms and conditions set forth in the Articles of Amendment.

 

“Registration Rights Agreement” means the Registration Rights Agreement, dated December 1, 2010, by and among Insmed and the shareholders named therein.

 

“Shareholder Approval” has the meaning set forth in the Articles of Amendment.

 

“Transfer” means to offer, sell, exchange, pledge, hypothecate, encumber, transfer, distribute, assign or otherwise dispose of, whether directly or indirectly or to enter into any swap or any other agreement, transaction or series of transactions that hedges or transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of Insmed Common Stock or Insmed Preferred Stock.

 

 

2. Governance Matters.

 

2.1 Board Composition.

 

(a)  Shareholders holding 62.5% of the outstanding Insmed Common Stock and Insmed Preferred Stock (on an as converted to Insmed Common Stock basis assuming the Shareholder Approval) then held by all Shareholders (the “Designating Shareholders”), shall have the right to nominate for election to the Board one (1) director (the “Designee”) at the first annual or special meeting of shareholders of Insmed after the Effective Time at which the Company Nominee (as defined in the Merger Agreement) or any director appointed to replace such Company Nominee is subject to election and at any subsequent annual or special meeting of shareholders of Insmed at which such Designee or any director appointed to replace such Designee is subject to election,  and Insmed shall, at any such annual or special meeting of shareholders of Insmed, subject to the fulfillment of the requirements set forth in Section 2.1(b), nominate the Designee for election to the Board and use commercially reasonable efforts to cause the Designee to be elected as a director of the Board.

 

Notwithstanding the foregoing in this Section 2.1(a), the Designating Shareholders shall cease to have any right to nominate the Designee for election to the Board following the earliest of (i) the five (5) year anniversary Effective Time, (ii) the conversion of the Insmed Preferred Stock into Insmed Common Stock and (iii) such time that the Shareholders and their Affiliates (including any limited partners, members or other similar equity holders of the forgoing that receive Insmed Preferred Stock or Common Stock as a distribution pursuant to such holder’s limited partnership agreement, limited liability company agreement, operating agreement or similar governing document) collectively no longer hold at least 6,484,705 shares of Insmed Common Stock issued pursuant to the Merger and at least 22,936,473 shares of Insmed Preferred Stock issued pursuant to the Merger (the “Minimum Share Amount”), provided that the Minimum Share Amount shall be appropriately adjusted for any stock dividends, splits, reverse splits, combinations recapitalizations and the like occurring after the date of this Agreement.

 

(b) Any designee for election to the Board in accordance with this Section 2 shall (i) be reasonably acceptable to the Board and the Board’s Corporate Governance Committee (the “Governance Committee”), it being agreed that Donald Hayden, Jr. is so acceptable, and (ii) shall comply in all respects with Insmed’s corporate governance guidelines and Insmed’s code of business conduct and ethics as in effect from time to time. The Designating Shareholders shall notify Insmed of any proposed Designee in writing no later than the latest date on which shareholders of Insmed may make nominations to the Board in accordance with the Bylaws, together with all information concerning such nominee required to be delivered to Insmed by the Bylaws then in effect and such other information reasonably requested by Insmed; provided that in each such case, all such information is generally required to be delivered to Insmed by the other outside directors of Insmed (the “Nominee Disclosure Information”); provided, further that in the event the Designating Shareholders fail to provide any such notice, the Designee shall be the Person then serving as the Designee as long as the Designating Shareholders provide the Nominee Disclosure Information to Insmed promptly upon request by Insmed.

 

(c) For so long as the Designated Shareholders shall have the right to nominate the Designee for election to the Board, Insmed shall invite a representative of the Designated Shareholders to attend all meetings of the Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and, provided further, that Insmed reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between Insmed and its counsel.

 

2.2 Compensation and Benefits. The Designee will be entitled to receive at a minimum the same compensation, benefits, reimbursement, indemnification and insurance coverage for their service as directors as the other outside directors of Insmed. Following the Effective Time, for so long as Insmed maintains directors and officers liability insurance, Insmed shall include the Designee as “insured” for all purposes under such insurance policy for so long as such Person is a director of Insmed and for the same period as for other former directors of Insmed when such Designee ceases to be a director of Insmed.

 

 

3. Restrictions on Transfer.

 

3.1 No Transfer of Capital Stock. Until May 30, 2011 each of the Shareholders agrees that it will not, directly or indirectly, Transfer any portion of any shares of Insmed Common Stock or any shares of Insmed Preferred Stock or shares of Insmed Common Stock issued upon a conversion of the Insmed Preferred Stock to any Person without the prior written consent of Insmed (which consent may be given or withheld, or made subject to such conditions as are determined by Insmed, in its sole discretion) other than (i) to its Affiliates (including its limited partners, members or other similar equity holders) or Affiliates of other Shareholders who execute a written joinder agreement in a form approved by Insmed pursuant to which such Affiliate agrees to be bound by the terms of Sections 3 and 4 of this Agreement, (ii) to other Shareholders, (iii) pursuant to a tender or exchange offer recommended by the Board, (iv) pursuant to a merger or consolidation recommended by the Board, or (v) solely with respect to the Beacon Bioventures Funds, Transfers to any Person in a private placement; provided that the maximum number of shares of Insmed Common Stock or Insmed Preferred Stock that Beacon Bioventures Funds is permitted to transfer pursuant to this clause (v) until May 30, 2011 shall be 7,600,000 (assuming that the Insmed Preferred Stock is converted into Insmed Common Stock on a one for one basis), and subject to adjustments for any stock splits, reverse stock splits, stock dividends and other similar transaction (transferees under clauses (i) through (v), are herein referred to as “Permitted Assigns”).  Any purported Transfer which is not in accordance with the terms and conditions of this Section 3.1 shall be, to the fullest extent permitted by law, null and void ab initio and, in addition to other rights and remedies at law and in equity, Insmed shall be entitled to injunctive relief enjoining the prohibited action.  

 

3.2 No Transfer to Competitors.  Each Shareholder agrees that it will not at any time knowingly directly Transfer any shares of Insmed Common Stock or any shares of Insmed Preferred Stock or any shares of Insmed Common Stock issuable upon conversion of the Insmed Preferred Stock to any Competitor of Insmed without the prior written consent of Insmed (which consent may be given or withheld, or made subject to such conditions as are determined by Insmed, in its sole and absolute discretion); provided, that the provisions of this Section 3.2 shall not apply to any tender or exchange offer with respect to a majority of the issued and outstanding capital stock of Insmed made by any such Competitor or to any sales made pursuant to open market transactions through a broker in which the transferring Shareholder does not know that the ultimate purchaser of such capital stock is a Competitor.

 

3.3 No Block Transfers to Individual Persons.  Each Shareholder agrees that it will not, and will cause its Affiliates not to, individually or acting together with any other Shareholder or its Affiliates, at any time knowingly directly Transfer any shares of Insmed Common Stock or any shares of Insmed Preferred Stock or any shares of Insmed Common Stock issuable upon conversion of the Insmed Preferred Stock, unless consented to by Insmed: (a) to any individual Person or “group” (within the meaning of Section 13(d)(3) of the Exchange Act) in an amount constituting 5% or more of the voting capital stock of Insmed then outstanding or (b) to any individual Person or “group” (within the meaning of Section 13(d)(3) of the Exchange Act) that, immediately following such Transfer, would beneficially own in the aggregate more than 15% of the voting capital stock of Insmed then outstanding (other than, in each case of clauses (a) or (b), to (i) any of its Permitted Assigns or (ii) an underwriter in connection with a bona fide public offering or distribution or a Person in a sale made pursuant to open market transactions through a broker in which the transferring Shareholder does not know that the ultimate purchaser of such capital stock would beneficially own in the aggregate more than 15% of the voting capital stock of Insmed then outstanding).

 

3.4 Registration Rights Agreement.  Each Shareholder hereby agrees that it will not, and will cause its Affiliates not to, sell any of its or their Registrable Securities (as defined in the Registration Rights Agreement) pursuant to Section 3, Section 4 or Section 5 of the Registration Rights Agreement, other than in accordance with this Section 3.4 and the terms of the Registration Rights Agreement.  Notwithstanding the foregoing, each Shareholder, together with its Affiliates, may only sell, in the aggregate, pursuant to Section 3, Section 4 or Section 5 of the Registration Rights Agreement, (i) one-third (1/3) of the Registrable Securities owned by such Shareholder as of the Closing Date during the period beginning on May 30, 2011 through the date that is six months from such date and (ii) an additional one-third (1/3) of the Registrable Securities owned by such Shareholder as of the date hereof during each six-month period thereafter (for the avoidance of doubt, each additional one-third (1/3) shall be cumulative and in addition to the amount such Shareholder and its Affiliates was otherwise permitted to sell pursuant to this Section 3.4 but did not sell).

 

 

4. Standstill Restrictions.  Commencing from the date hereof until June 1, 2012 (the “Standstill Termination Date”), each of the Shareholders shall not, and shall cause its respective Affiliates (including commonly controlled or managed investment funds) not to, unless consented to or requested by Insmed, as a director of Insmed or as otherwise permitted hereby: (i) directly acquire, agree to acquire, or offer to acquire, beneficial ownership of any equity or debt securities of Insmed, any warrant or option to purchase such securities, any security convertible into any such securities, or any other right to acquire such securities, other than the Insmed Common Stock received upon conversion of shares of Insmed Preferred Stock and any shares of Insmed Preferred Stock or Insmed Common Stock paid as dividends, (ii)  enter into or agree to enter into any merger, business combination, recapitalization, restructuring, change of control transaction or other extraordinary transaction involving Insmed or any of its Subsidiaries, other than in connection with a third party tender or exchange offer or other transaction approved by Insmed, (iii) make, or in any way participate or engage in, directly or indirectly, any solicitation of proxies to vote, or seek to advise or influence any Person with respect to the voting of, any voting securities of Insmed, (iv) bring any action or otherwise act to contest the validity of the restrictions set forth in this Section 4, or seek a release of such restrictions, (v) form, join or in any way participate in a “group” (within the meaning of Section 13(d)(3) of the Exchange Act) with respect to any voting securities of Insmed or any Subsidiary of Insmed (including, without limitation, any group constituting of Shareholders and their respective Affiliates) (other than to nominate and vote for a Designee following a breach by Insmed of its covenants in Section 2 hereof), (vi)  propose or enter into any discussions, negotiations, arrangements, understandings or agreements (whether written or oral) with any other Person regarding any possible purchase of any securities or assets of Insmed, (vii) call, request the calling of, or otherwise seek or assist in the calling of a special meeting of the shareholders of Insmed, (viii) grant any proxy with respect to any shares of Insmed Common Stock, Insmed Preferred Stock or Insmed Common Stock issuable upon conversion of the Insmed Preferred Stock to any Person not affiliated with the Shareholder or Insmed (other than in connection with the granting of a proxy to vote for a Designee following a breach of Insmed of its covenants in Section 2 hereof); or (x) disclose any intention, plan or arrangement prohibited by, or inconsistent with, the foregoing; provided, however, that the foregoing shall not restrict the ability of the Designees or other directors appointed or elected to the Board pursuant to the terms of this Agreement from exercising their fiduciary duties.

 

 

5. Capital Stock of Insmed.  Each Shareholder represents and warrants to Insmed that, as of the date of this Agreement, neither it nor any of its Affiliates, directly or indirectly, owns any capital stock of Insmed.

 

 

6. Public Announcements.  The Shareholders shall consult with Insmed before issuing, and provide Insmed the opportunity to review, comment upon and concur with, any press release or other public statement with respect to this Agreement, the Merger Agreement, the Merger and the other transactions contemplated by this Agreement or the Merger Agreement and none of the Shareholders shall issue any press release or make any such public statement prior to such consultation, except as may be required by Legal Requirement.

 

 

7. Termination.  Other than the termination provisions applicable to particular Sections of this Agreement that are specifically provided elsewhere in this Agreement, this Agreement shall terminate (except for Section 8) (a) upon the mutual written agreement of Insmed and the Designating Shareholders or (b) with respect to any Shareholder, at such time as the Shareholder no longer beneficially owns any shares of Insmed Common Stock or any shares of Insmed Preferred Stock.

 

 

8. Confidentiality.

 

8.1 Each Shareholder (each a “Receiving Party”) hereby agrees to keep, and to cause each of its Affiliates and each of their respective employees, officers, directors, accountants, counsel, consultants, advisors and agents to keep confidential, any and all confidential information of Transave, Insmed and their respective Subsidiaries, including non-public information relating to Transave’s, Insmed’s and their respective Subsidiaries’ technologies, clinical studies, regulatory affairs, finances and results, trade secrets, know-how, customers, business plans, marketing activities, financial data and other business affairs that was disclosed to Receiving Party by Transave or Insmed or their respective Subsidiaries on or prior to the date of this Agreement or that is disclosed to Receiving Party on or after the date of this Agreement by Transave or Insmed or their respective Subsidiaries or any other Shareholder or their respective Affiliates or representatives, (collectively, the “Insmed Proprietary Information”), and to utilize Insmed Proprietary Information only for the purpose for which such information was disclosed (the “Utilization Restriction”); provided, however, that the Utilization Restriction shall not restrict the sale by Receiving Party of the shares of Insmed Common Stock or Insmed Preferred Stock or the Insmed Common Stock issuable upon conversion of the Insmed Preferred Stock so long as such Receiving Party complies with the confidentiality restrictions of this section; provided, further, however, that Insmed Proprietary Information shall not include any information that (i) is or subsequently becomes generally publicly available without breach of this Section 7 or (ii) is or subsequently becomes known or available to a Receiving Party on a non-confidential basis from a source other than Insmed, Transave or their respective Subsidiaries and representatives that, to such Receiving Party’s knowledge, is not prohibited from disclosing such Insmed Proprietary Information to the Receiving Party by a contractual, legal or fiduciary obligation owed by such other third party.  For the avoidance of doubt, subject to the terms of this Section 8.1, any Receiving Party may disclose Insmed Proprietary Information to its Affiliates and its and its Affiliates’ employees, officers, directors, accountants, counsel, consultants, advisors and agents.  Each Receiving Party shall be responsible for any failure of its and its Affiliates' employees, officers, directors, accountants, counsel, consultants, advisors and agents to keep confidential the Insmed Proprietary Information and to comply with the Utilization Restriction.  The obligation of each Receiving Party to hold and to cause its Affiliates to hold any such information in confidence shall be satisfied if it exercises at least the same care with respect to such information as it would take to preserve the confidentiality of its own information, but not less than reasonable care.

 

8.2 In the event that any Receiving Party is required by applicable law, regulation or legal process to disclose any Insmed Proprietary Information, then (to the extent reasonably practicable, before substantively responding to any such request or requirement) such Receiving Party will provide Insmed with prompt written notice of any such request or requirement so that Insmed may (at its sole cost and expense) seek a protective order or other appropriate remedy, or both, or waive compliance with the provisions of this Section 8.2 or other appropriate remedy, or if Insmed so directs, such Receiving Party will exercise its own commercially reasonable efforts to assist Insmed in obtaining a protective order or other appropriate remedy at Insmed’s sole cost and expense.  If, failing the entry of a protective order or other appropriate remedy or the receipt of a waiver hereunder, disclosure of any Insmed Proprietary Information is required by law, regulation or legal process then such Receiving Party may furnish only that portion of the Insmed Proprietary Information that is required to be so furnished pursuant to law, regulation or legal process.  In any event, such Receiving Party will, to the extent practicable and permissible by law cooperate fully with any action by Insmed (at its sole cost and expense) to obtain an appropriate protective order or other reliable assurance that confidential treatment will be accorded the Insmed Proprietary Information.  Notwithstanding the foregoing, the Receiving Party shall not be obligated to provide Insmed with notice of any request for Insmed Proprietary Information from any Governmental Body if disclosing such request would be in violation of any applicable law, rule or regulation or if such request is received pursuant to regulatory oversight (and the Receiving Party shall be entitled to comply with any such request without providing such notification).

 

 

9. Miscellaneous.

 

9.1 Notices.  Any notice or other communication required or permitted to be delivered to any party under this Agreement shall be in writing and shall be deemed properly delivered, given and received: (a) if delivered by hand, when delivered; (b) if sent via facsimile with confirmation of receipt, when transmitted and receipt is confirmed; (c) if sent by electronic mail, telegram, cablegram or other electronic transmission, upon delivery; (d) if sent by registered, certified or first class mail, the third Business Day after being sent; and (e) if sent by overnight delivery via a national courier service, one Business Day after being sent, in each case to the address or facsimile telephone number set forth beneath the name of such party below (or to such other address or facsimile telephone number as such party shall have specified in a written notice given to the other parties hereto):

 

If to Insmed, to:

8720 Stony Point Parkway, Suite 200

Richmond, Virginia, 23235

Attention: Mr. W. McIlwaine Thompson, Secretary

Telecopy:  (434) 977-7920

 

 

with a copy (which shall not constitute notice) to:

 

 

Greenberg Traurig, LLP

 

200 Park Avenue

 

New York, NY 10166

 

Attention:  Joseph A. Herz

 

Facsimile:  (212) 805-5539

 

If to any Shareholder, to the address specified in Schedule I.

 

 

Notwithstanding anything to the contrary contained herein, any notice received on any Business Day after 5:00 p.m. (addressee’s local time) or on a day that is not a Business Day shall be deemed to have been received at 9:00 a.m. (addressee’s local time) on the next Business Day.

 

9.2 Headings.  The underlined headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.

 

9.3 Counterparts and Exchanges by Electronic Transmission or Facsimile.  This Agreement may be executed in several counterparts, each of which shall constitute an original and all of which, when taken together, shall constitute one agreement.  The exchange of a fully executed Agreement (in counterparts or otherwise) by electronic transmission in PDF format or by facsimile shall be sufficient to bind the parties to the terms and conditions of this Agreement.

 

9.4 Governing Law.  This Agreement shall be construed in accordance with, and governed in all respects by, the internal laws of the State of New York (without giving effect to principles of conflicts of laws).

 

9.5 Venue.  Any Legal Proceeding relating to this Agreement or the enforcement of any provision of this Agreement (including a Legal Proceeding based upon intentional misrepresentation or fraud) may be brought or otherwise commenced in any state or federal court located in the Borough of Manhattan in the State of New York.  Each party to this Agreement: (i) expressly and irrevocably consents and submits to the exclusive jurisdiction of each state and federal court located in the Borough of Manhattan in the State of New York (and each appellate court located in the State of New York) in connection with any such Legal Proceeding; (ii) agrees that each state and federal court located in the Borough of Manhattan in the State of New York shall be deemed to be a convenient forum; and (iii) agrees not to assert (by way of motion, as a defense or otherwise), in any such Legal Proceeding commenced in any state or federal court located in the Borough of Manhattan in the State of New York, any claim that such party is not subject personally to the jurisdiction of such court, that such Legal Proceeding has been brought in an inconvenient forum, that the venue of such proceeding is improper or that this Agreement or the subject matter of this Agreement may not be enforced in or by such court.

 

9.6 Successors and Assigns.  Except as otherwise provided in this Agreement, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors, and administrators of the parties; provided, however, the rights of the Shareholders under this Agreement shall not be assignable to any Person without the consent of Insmed; provided, further, that the provisions of this Agreement shall not apply to any Person to whom any shares of Insmed Preferred Stock or shares of Insmed Common Stock are Transferred (and who has not entered into a joinder agreement) so long as such Transfer is not made in violation of this Agreement.

 

9.7 Specific Performance.  The parties to this Agreement agree that irreparable damage would occur in the event that the provisions contained in this Agreement were not performed in accordance with its specific terms or were otherwise breached.  It is accordingly agreed that, in the event of any breach or threatened breach by any party to this Agreement of any covenant, obligation or other provision set forth in this Agreement, for the benefit of any other party to this Agreement: (a) such other party shall be entitled (in addition to any other remedy that may be available to it at law or in equity) to: (i) a decree or order of specific performance or mandamus to enforce the observance and performance of such covenant, obligation or other provision; and (ii) an injunction restraining such breach or threatened breach; and (b) such other party shall not be required to provide any bond or other security in connection with any such decree, order or injunction or in connection with any related action or Legal Proceeding.

 

9.8 Waiver.  No failure on the part of any Person to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Person in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.  No Person shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Person; and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.

 

9.9 Waiver of Jury Trial.   EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).  EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

 

9.10 Amendments.  This Agreement may not be amended, modified, altered or supplemented other than by means of a written instrument duly executed and delivered by the parties hereto or, in the case of a waiver, by the party against whom the waiver is to be effective.  Any amendment or waiver effected in accordance with this paragraph shall be binding upon each party hereto.

 

9.11 Severability.  In the event that any provision of this Agreement, or the application of any such provision to any Person or set of circumstances, shall be determined to be invalid, unlawful, void or unenforceable to any extent by any court of competent jurisdiction, the remainder of this Agreement, and the application of such provision to Persons or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, shall not be impaired or otherwise affected and shall continue to be valid and enforceable to the fullest extent permitted by law and the parties shall use their commercially reasonable efforts to substitute a valid, legal and enforceable provision which, insofar as practicable, implements the original purposes and intents of this Agreement.

 

9.12 Parties-in-Interest.  None of the provisions of this Agreement is intended to provide any rights or remedies to any Person other than the parties hereto and their respective successors and assigns (if any).

 

9.13 Entire Agreement.  This Agreement, the Merger Agreement, the Registration Rights Agreement and the other agreements and documents delivered by the parties in connection herewith constitute the entire understanding of the parties hereto relating to the subject matter hereof and thereof and supersede all prior agreements and understandings among or between any of the parties relating to the subject matter hereof and thereof.

 

9.14 Construction.

 

(a) Gender; Etc.  If a term is defined as one part of speech (such as a noun), it shall have a corresponding meaning when used as another part of speech (such as a verb).  Unless indicated otherwise, terms defined in the singular have the corresponding meanings in the plural, and vice versa.  Unless the context of this Agreement clearly requires otherwise, words importing the masculine gender shall include the feminine and neutral genders and vice versa.  The words “hereof,” “hereto,” “hereby,” “herein,” “hereunder” and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular section or article in which such words appear.  Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless Business Days are specified.  Whenever any action must be taken hereunder on or by a day that is not a Business Day, then such action may be validly taken on or by the next day that is a Business Day.  The use of “or” is not intended to be exclusive unless expressly indicated otherwise.  No provision of this Agreement shall be construed to require any party to this Agreement to take action that would violate applicable Legal Requirements.

 

(b) Ambiguities.  Each party hereto acknowledges that it and its attorney has reviewed this Agreement and agrees that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.

 

(c) Including.  As used in this Agreement, the words “include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.”

 

(d) References.  All article, section, schedule, exhibit and annex references used in this Agreement are to articles, sections, schedules, exhibits and annexes to this Agreement unless otherwise specified.  The schedules, exhibits and annexes attached to this Agreement constitute a part of this Agreement and are incorporated herein for all purposes.  The captions in this Agreement are for convenience only and shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement.

 

  

  

  

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

 

INSMED INCORPORATED

 

 

	
  

	
By:

	
/s/ Kevin P. Tully

	 

	
  

	
Name:  Kevin P. Tully

	
  

	
Title:    Executive Vice President and Chief   Financial Officer

 

 

  

  

  

 

Shareholders

 

PROSPECT VENTURES PARTNERS III, L.P.

 

By: Prospect Management Co. III, L.L.C.

Its: General Partner

 

 

	
  

	
By:

	
/s/ Alex Barkas

	 

 

	
  

	
Name:  Alex Barkas

 

	
  

	
Title:    Managing Member

 

 

 

QUAKER BIOVENTURES II, L.P.

 

By: QUAKER BIOVENTURES CAPITAL II, L.P.

Its: General Partner

	
  

	
By: QUAKER BIOVENTURES CAPITAL II, LLC

Its: General Partner

By: __/s/ Richard Kollender__________________

Name: Richard Kollender

Title:   Vice President

 

 

BESSEMER VENTURE PARTNERS VII INSTITUTIONAL L.P.

 

	
  

	
By: Deer VII & Co. L.P.

	
  

	
Its:  General Partner

By: Deer VII & Co. Ltd.

Its: General Partner

 

	
  

	
By:

	
/s/ J.Edmond Colloton

 

	
  

	
Name:  J. Edmond Colloton

 

	
  

	
Title:   Director

 

 

BESSEMER VENTURE PARTNERS VII, L.P.

 

	
  

	
By: Deer VII & Co. L.P.

	
  

	
Its:  General Partner

By: Deer VII & Co. Ltd.

Its: General Partner

 

	
  

	
By:

	
/s/ J.Edmond Colloton

 

	
  

	
Name:  J. Edmond Colloton

 

	
  

	
Title:   Director

 

CHRISTOPHER GABRIELI

 

By: /s/ Christopher Gabrieli                                                                           

 

 

SETH ORLOW

 

By: /s/ Seth Orlow                                                                           

 

 

TVM V LIFE SCIENCE VENTURES GmbH & Co. KG

	
  

	
By: /s/ Mark G. Cipriano   /s/ David Poltack

Name: Mark G. Cipriano   David Poltack

Title:  Managing Limited Partners

TVM IV GmbH & Co. KG

	
  

	
By: /s/ Mark G. Cipriano   /s/ David Poltack

Name: Mark G. Cipriano   David Poltack

Title:  Authorized Signatories

 

EASTON HUNT CAPITAL PARTNERS, L.P.

	
  

	
By: EHC GP, L.P.

	
  

	
Its:  General Partner

By: EHC, Inc.

Its: General Partner

 

	
  

	
By:

	
/s/ Richard P. Schneider

	 

 

	
  

	
Name:  Richard P. Schneider

 

	
  

	
Title:    Vice President & Secretary

 

 

 

BEACON BIOVENTURES LIMITED PARTNERSHIP

	
  

	
By:  Beacon Bioventures Advisors, L.P.

	
  

	
Its:  General Partner

By: Fidelity Biosciences Corp.

Its: General Partner

 

	
  

	
By:

	
/s/ Richard W. Fedorowich, Jr.

	 

 

	
  

	
Name:  Richard P. Fedorowich, Jr.

 

	
  

	
Title:    Chief Financial Officer

 

 

 

BEACON BIOVENTURES PRINCIPALS LIMITED PARTNERSHIP

	
  

	
By:  Beacon Bioventures Advisors, L.P.

	
  

	
Its:   General Partner

By: Fidelity Biosciences Corp.

Its: General Partner

 

	
  

	
By:

	
/s/ Richard W. Fedorowich, Jr.

	 

 

	
  

	
Name:  Richard P. Fedorowich, Jr.

 

	
  

	
Title:    Chief Financial Officer

 

 

	
  

	
COOPERATIEVE AAC LS U.A.

 

	
 

	 By: /s/ M.A. van Osch   /s/ G.J. Mulder

Name: M.A. van Osch G.J. Mulder

Title:  Partnersiex4-2.htm

REGISTRATION RIGHTS AGREEMENT

 

 

 

by and among

 

 

 

INSMED INCORPORATED

 

and the SHAREHOLDERS named herein

 

 

Dated:  December 1, 2010

 

  

  

  

TABLE OF CONTENTS

 

	
Definitions

	
1.(a)

	
Interpretation

	  	
(b)

	
General; Securities Subject to this Agreement

	
2

	
Grant of Rights

	  	
(a)

	
Registrable Securities

	  	
(b)

	
Holders of Registrable Securities

	  	
(c)

	
Transfer of Registration Rights

	  	
(d)

	
Demand Registration

	
3

	
Request for Demand Registration

	  	
(a)

	
Incidental or “Piggy-Back” Rights with Respect to a Demand Registration

	  	
(b)

	
Effective Demand Registration

	  	
(c)

	
Expenses

	  	
(d)

	
Underwriting Procedures

	  	
(e)

	
Selection of Underwriters

	  	
(f)

	
Withdrawal

	  	
(g)

	
Incidental or “Piggy-Back” Registration

	
4

	
Request for Incidental or “Piggy-Back” Registration

	  	
(a)

	
Expenses

	  	
(b)

	
Form S‐3 Registration

	
5

	
Form S‐3 Registration

	  	
(a)

	
Form S-3 Underwriting Procedures

	  	
(b)

	
Limitations on Form S‐3 Registrations

	  	
(c)

	
Expenses

	  	
(d)

	
Automatic Shelf Registration Statement

	  	
(e)

	
Shelf Take-Downs

	  	
(f)

	
Holdback Agreements

	
6

	
Restrictions on Public Sale by Designated Shareholders

	  	
(a)

	
Restrictions on Public Sale by Insmed

	  	
(b)

	
Registration Procedures

	
7

	
Obligations of Insmed

	  	
(a)

	
Seller Requirements

	  	
(b)

	
Notice to Discontinue

	  	
(c)

	
Registration Expenses

	  	
(d)

	
Indemnification; Contribution

	
8

	
Indemnification by Insmed

	  	
(a)

	
Indemnification by Designated Shareholders

	  	
(b)

	
Conduct of Indemnification Proceedings

	  	
(c)

	
Contribution

	  	
(d)

	
Rule 144

	
9

	
Miscellaneous

	
10

	
Stock Splits, etc.

	  	
(a)

	
Inconsistent Agreements

	  	
(b)

	
Remedies

	  	
(c)

	
Amendments and Waivers

	  	
(d)

	
Notices

	  	
(e)

	
Permitted Assignees; Third Party Beneficiaries

	  	
(f)

	
Aggregation of Stock

	  	
(g)

	
Counterparts

	  	
(h)

	
Headings

	  	
(i)

	
Governing Law

	  	
(j)

	
Jurisdiction

	  	
(k)

	
Waiver of Jury Trial

	  	
(l)

	
Severability

	  	
(m)

	
Rules of Construction

	  	
(n)

	
Entire Agreement

	  	
(o)

	
Further Assurances

	  	
(p)

	
Other Agreements

	  	
(q)

  

  

  

REGISTRATION RIGHTS AGREEMENT

 

REGISTRATION RIGHTS AGREEMENT, dated as of December 1, 2010, by and among Insmed Incorporated, a Virginia corporation (the “Insmed”), and the shareholders that are party to this Agreement from time to time, as set forth on the signature page hereto (each, a “Designated Shareholder”).

 

WHEREAS, pursuant to that certain Agreement and Plan of Merger, dated as of December 1, 2010 (the “Merger Agreement”), by and among Insmed, River Acquisition Co., a Delaware corporation and a wholly-owned subsidiary of Insmed, Transave, LLC, a Delaware limited liability company, the sole member of which is Insmed, Transave, Inc., a Delaware corporation, and the Shareholders’ Agent (as defined therein), the Designated Shareholders have been or may be issued, under the circumstances described in Section 1.5 of the Merger Agreement, shares of common stock, par value $0.01 per share, of Insmed (“Common Stock”) and shares of Series B Conditional Convertible Preferred Stock, par value $0.01 per share, of Insmed (“Preferred Stock”) which are convertible into shares of Common Stock subject to the terms of the Articles of Amendment to the Articles of Incorporation of Insmed, as amended, creating such Preferred Stock;

 

WHEREAS, the shares of Common Stock and Preferred Stock issued (and to be issued) to the Designated Shareholders in connection with the transactions contemplated in the Merger Agreement have not been registered under the Securities Act (as hereinafter defined) or any state securities laws; and the certificates representing such shares bear a legend restricting their transfer; and

 

WHEREAS, Insmed desires to provide for, among other things, the grant of registration rights with respect to the Registrable Securities (as hereinafter defined) to the Designated Shareholders.

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

 

1. (a)           Definitions

 

As used in this Agreement, and unless the context requires a different meaning, the following terms have the meanings indicated:

 

“Affiliate” means, with respect to a Person, any other Person directly or indirectly controlling or controlled by or under direct or indirect common control with such specified Person.  For purposes of this definition, “control” (including, with correlative meanings, the terms “controlling,” “controlled by” and “under common control with”), as used with respect to a Person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person, whether through the ownership of voting securities, by agreement or otherwise.

 

“Agreement” means this Registration Rights Agreement as the same may be amended, supplemented or modified in accordance with the terms hereof.

 

“Approved Underwriter” has the meaning set forth in Section 3(f) hereof.

 

“Automatic Shelf Registration Statement” means an “automatic shelf registration statement” as defined in Rule 405 promulgated under the Securities Act.

 

“Board of Directors” means the Board of Directors of Insmed (or any duly authorized committee thereof).

 

“Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks in the State of New York are authorized or required by law or executive order to close.

 

“Closing Price” means, with respect to the Registrable Securities, as of the date of determination, (a) if the Registrable Securities are listed on a national securities exchange, the closing price per share of a Registrable Security on such date published in The Wall Street Journal (National Edition) or, if no such closing price on such date is published in The Wall Street Journal (National Edition), the average of the closing bid and asked prices on such date, as officially reported on the principal national securities exchange on which the Registrable Securities are then listed or admitted to trading; or (b) if the Registrable Securities are not listed or admitted to trading on any national securities exchange, the last sale price or, if such last sale price is not reported, the average of the high bid and low asked prices on the automatic quotation system on which the Registrable Securities are then listed, as reported by Bloomberg Financial Markets (or any successor thereto); or (c) if on any such date the Registrable Securities are not quoted on any such automatic quotation system, the average of the closing bid and asked prices as furnished by a professional market maker making a market in the Registrable Securities selected by Insmed; or (d) if none of (a), (b) or (c) is applicable, a market price per share determined in good faith by the Board of Directors or, if such determination is not satisfactory to the Designated Shareholders for whom such determination is being made, by a nationally recognized investment banking firm selected by Insmed and such Designated Shareholders, the expenses for which shall be borne by such Designated Shareholders.  If trading is conducted on a continuous basis on any exchange, then the closing price shall be as set forth at 4:00 P.M. New York City time.

 

“Commission” means the Securities and Exchange Commission or any similar agency then having jurisdiction to enforce the Securities Act.

 

“Common Stock” means (i) the Common Stock of Insmed, (ii) any securities of Insmed or any successor or assign of Insmed into which such stock described in clause (i) is reclassified or reconstituted or into which such stock is converted or otherwise exchanged in connection with a combination of shares, recapitalization, merger, sale of assets, consolidation or other reorganization or otherwise or (iii) any securities received as a dividend or distribution in respect of the securities described in clauses (i) or (ii) above.

 

“Demand Registration” has the meaning set forth in Section 3(a) hereof.

 

“Designated Shareholder” has the meaning set forth in the preamble to this Agreement.

 

“Designated Shareholders’ Counsel” has the meaning set forth in Section 7(a)(i) hereof.

 

“Disclosure Package” means, with respect to any offering of Registrable Securities, (i) the preliminary Prospectus, (ii) each Free Writing Prospectus and (iii) all other information, in each case, that is deemed, under Rule 159 promulgated under the Securities Act, to have been conveyed to purchasers of securities at the time of sale of such securities (including, without limitation, a contract of sale).

 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.

 

“FINRA” means the Financial Industry Regulatory Authority, Inc.

 

“Form S-3 Shelf Registration Statement” has the meaning set forth in Section 5(a) hereof.

 

“Free Writing Prospectus” means any “free writing prospectus” as defined in Rule 405 promulgated under the Securities Act.

 

“Incidental Registration” has the meaning set forth in Section 4(a) hereof.

 

“Incidental Registration Notice” has the meaning set forth in Section 4(a) hereof.

 

“Indemnified Party” has the meaning set forth in Section 8(c) hereof.

 

“Indemnifying Party” has the meaning set forth in Section 8(c) hereof.

 

“Initiating Holders” means, at any time, the Majority Designated Shareholders.

 

“Initiating Shelf Holder” has the meaning set forth in Section 5(f) hereof.

 

“Insmed” has the meaning set forth in the preamble to this Agreement.

 

“Insmed Free Writing Prospectus” means each Free Writing Prospectus prepared by or on behalf of Insmed or used or referred to by Insmed in connection with an offering of Registrable Securities.

 

“Insmed Underwriter” has the meaning set forth in Section 4(a) hereof.

 

“Inspector” has the meaning set forth in Section 7(a)(i) hereof.

 

“Liability” has the meaning set forth in Section 8(a) hereof.

 

“Majority Designated Shareholders” means beneficial owners of Registrable Securities representing more than 50% of the total number of outstanding Registrable Securities.

 

“Majority Initiating Holders” means Initiating Holders holding a majority of the Registrable Securities held by all of the Initiating Holders.

 

“Majority S-3 Participating Shareholders” means S-3 Participating Shareholders holding a majority of the Registrable Securities included in an S-3 Registration.

 

“Majority Shelf Take-Down Shareholders” means S-3 Participating Shareholders holding a majority of the Registrable Securities included in a Shelf Take-Down.

 

“Market Price” means, on any date of determination, the average of the daily Closing Price of the Registrable Securities for the immediately preceding thirty days on which the national securities exchanges are open for trading; provided, however, that if the Closing Price is determined pursuant to clause (d) of the definition of Closing Price, the “Market Price” means such Closing Price on the date of determination.

 

“Marketed Underwritten Shelf Take-Down”  has the meaning set forth in Section 5(f) hereof.

 

“Non-Marketed Underwritten Shelf Take-Down”  has the meaning set forth in Section 5(f) hereof.

 

“Permitted Assignee” means, with respect to any Person, to the extent applicable, (i) such Person’s parents, spouse, siblings, siblings’ spouses, children (including stepchildren and adopted children), children’s spouses, grandchildren or grandchildren’s spouses (“Family Members”), (ii) a corporation, partnership or limited liability company, a majority of the beneficial interests of which shall be held by such Person, such Person’s Affiliates and/or such Person’s Family Members, (iii) a trust, the beneficiaries of which are such Person and/or such Person’s Family Members, (iv) such Person’s heirs, executors, administrators, estate or a trust under such Person’s will, (v) an entity described in Section 501(c)(3) of the United States Internal Revenue Code of 1986, as amended, that is established by such Person, (vi) any Affiliate of such Person, (vii) another Designated Shareholder or Affiliate of another Designated Shareholder, and (viii) if such Person is a corporation, partnership or limited liability company, any wholly-owned subsidiary of such entity or the partners, members, stockholders or Affiliates of such entity.

 

“Permitted Withdrawal” has the meaning set forth in Section 3(g) hereof.

 

“Person” means any individual, firm, corporation, partnership, limited liability company, trust, incorporated or unincorporated association, joint venture, joint stock company, limited liability company, government (or an agency or political subdivision thereof) or other entity of any kind, and shall include any successor (by merger or otherwise) of such entity.

 

“Pledgee” has the meaning set forth in Section 2(d)(i) hereof.

 

“Prospectus” means the prospectus related to any Registration Statement (including, without limitation, a prospectus or prospectus supplement that discloses information previously omitted from a prospectus filed as part of an effective registration statement in reliance on Rule 415, 430A, 430B or 430C under the Securities Act, as amended or supplemented by any amendment or prospectus supplement), including post-effective amendments, and all materials incorporated by reference in such prospectus.

 

“Records” has the meaning set forth in Section 7(a)(viii) hereof.

 

“Registrable Securities” means, subject to Section 2(b) and Section 2(d)(i) hereof, (i) any and all shares of Common Stock issued or to be issued to the Designated Shareholders in connection with the transactions contemplated by the Merger Agreement, (ii) any and all shares of Common Stock issued upon conversion of shares of Preferred Stock issued or to be issued to the Designated Shareholders in connection with the transactions contemplated by the Merger Agreement, and (iii) any shares of capital stock of any Person issued or issuable with respect of such shares of Common Stock as a result of any stock split, stock dividend, recapitalization, exchange, merger, consolidation or similar event.

 

“Registration Expenses” has the meaning set forth in Section 7(d) hereof.

 

“Registration Statement” means a registration statement filed pursuant to the Securities Act.

 

“S-3 Participating Shareholders” means all Designated Shareholders whose shares are included in an S-3 Registration.

 

“S-3 Registration” has the meaning set forth in Section 5(a) hereof.

 

“Seasoned Issuer” means an issuer eligible to use Form S-3 or F-3 for a primary offering of securities in reliance on General Instruction I.B.1 to such Form.

 

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder.

 

“Shelf Take-Down”  has the meaning set forth in Section 5(f) hereof.

 

“Specified Period” means 90 days; provided that if (i) Insmed issues an earnings release or other material news or a material event relating to Insmed and its subsidiaries occurs during the last 17 days of such period or (ii) prior to the expiration of such period, Insmed announces that it will release earnings results during the 16-day period beginning upon the expiration of such period, then to the extent necessary for a managing or co-managing underwriter of a registered offering required hereunder to comply with NASD Rule 2711(f)(4), such period shall be extended until 18 days after the earnings release or the occurrence of the material news or event, as the case may be.

 

“Target Filing Date”  means May 30, 2011.

 

“underwritten public offering” of securities means a public offering of such securities registered under the Securities Act in which an underwriter, placement agent or other intermediary participates in the distribution of such securities.

 

“Underwritten Shelf Take-Down”  has the meaning set forth in Section 5(f) hereof.

 

“Underwritten Shelf Take-Down Notice”  has the meaning set forth in Section 5(f) hereof.

 

“Valid Business Reason” has the meaning set forth in Section 3(a) hereof.

 

“Well-Known Seasoned Issuer” means a “well-known seasoned issuer” as defined in Rule 405 promulgated under the Securities Act and which (a) is a “well-known seasoned issuer” under paragraph (1)(i)(A) of such definition or (b) is a “well-known seasoned issuer” under paragraph (1)(i)(B) of such definition and is also eligible to use Form S-3 to register a primary offering of securities in reliance on General Instruction I.B.1 to such Form.

 

(b) Interpretation

 

Unless otherwise noted:

 

(i) All references to laws, rules, regulations and forms in this Agreement shall be deemed to be references to such laws, rules, regulations and forms, as amended from time to time or, to the extent replaced, the comparable successor laws, rules, regulations and forms thereto in effect at the time.

 

(ii) All references to agencies, self-regulatory organizations or governmental entities in this Agreement shall be deemed to be references to the comparable successor thereto.

 

(iii) All references to agreements and other contractual instruments shall be deemed to be references to such agreements or other instruments as they may be amended, waived, supplemented or modified from time to time.

 

(iv) All references to any amount of securities (including Registrable Securities) shall be deemed to be a reference to such amount measured on an as-converted or as-exercised basis.

 

2. General; Securities Subject to this Agreement

 

(a) Grant of Rights

 

Insmed hereby grants registration rights to the Designated Shareholders with respect to the Registrable Securities held by such Designated Shareholders upon the terms and conditions set forth in this Agreement.

 

(b) Registrable Securities

 

For the purposes of this Agreement, Registrable Securities held by any Designated Shareholder will cease to be Registrable Securities, when (i) a Registration Statement covering such Registrable Securities has been declared effective under the Securities Act by the Commission and such Registrable Securities have been disposed of pursuant to such effective Registration Statement, (ii) in the opinion of counsel reasonably satisfactory to Insmed, the entire amount of the Registrable Securities held by any Designated Shareholder may be sold in a single sale, without any limitation as to volume or manner of sale pursuant to Rule 144 promulgated under the Securities Act or (iii) the Registrable Securities have ceased to be outstanding.

 

(c) Holders of Registrable Securities

 

A Person is deemed to be a holder of Registrable Securities whenever such Person owns of record Registrable Securities.  If Insmed receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities, Insmed may act upon the basis of the instructions, notice or election received from the registered owner of such Registrable Securities.

 

(d) Transfer of Registration Rights

 

(i) Subject to the Shareholders’ Agreement, dated as of the date hereof, between Insmed and each of the Designated Holders, each Designated Shareholder may transfer or pledge Registrable Securities with the associated registration rights under this Agreement (including transfers occurring by operation of law or by reason of intestacy) to a Permitted Assignee or a pledgee (“Pledgee”) only if (1) such Permitted Assignee or Pledgee agrees in writing to be bound as a Designated Shareholder by the provisions of this Agreement, such agreement being substantially in the form of Annex A hereto, and (2) immediately following such transfer or pledge, the further disposition or transfer of such Registrable Securities by such Permitted Assignee or Pledgee would be restricted under the Securities Act and, in the opinion of counsel reasonably satisfactory to Insmed, the entire amount of all such Registrable Securities could not be sold in a single sale, without any limitation as to volume or manner of sale pursuant to Rule 144 promulgated under the Securities Act.  Upon any transfer or pledge of Registrable Securities other than as set forth in this Section 2(d), such securities shall no longer constitute Registrable Securities.

 

(ii) Subject to Section 2(b) hereof, if a Designated Shareholder assigns its rights under this Agreement in connection with the transfer of less than all of its Registrable Securities, the Designated Shareholder shall retain its rights under this Agreement with respect to its remaining Registrable Securities.  If a Designated Shareholder assigns its rights under this Agreement in connection with the transfer of all of its Registrable Securities, such Designated Shareholder shall have no further rights or obligations under this Agreement, except under Section 8 hereof in respect of offerings in which it participated.

 

3. Demand Registration

 

(a) Request for Demand Registration

 

.  To the extent permitted by applicable law and regulations, at any time that Insmed is not eligible to use Form S-3 under the Securities Act in connection with a secondary public offering of its equity securities after May 30, 2011, the Initiating Holders may make a written request to Insmed to register, and Insmed shall register, under the Securities Act (other than pursuant to a Registration Statement on Form S-4 or S-8), in accordance with the terms of this Agreement (a “Demand Registration”), the number of Registrable Securities stated in such request; provided, however, that Insmed shall not be obligated to effect (i) more than two (2) such Demand Registrations, (ii) a Demand Registration if the Initiating Holders propose to sell Registrable Securities in such Demand Registration at an anticipated aggregate offering price (calculated based upon the Market Price of the Registrable Securities on the date on which Insmed receives the written request for such Demand Registration) to the public of less than $10,000,000 unless such Demand Registration includes all of the then-outstanding Registrable Securities or (iii) any such Demand Registration within the Specified Period (or such shorter period as Insmed may determine in its sole discretion) after the effective date of any other Registration Statement of Insmed (other than a Registration Statement on Form S-4 or S-8).  For purposes of the preceding sentence, two or more Registration Statements related to the same offering by virtue of Rule 462(b) filed in response to one demand shall be counted as one Demand Registration.  In addition, if (1) the Board of Directors, in its good faith judgment, determines that any registration of Registrable Securities should not be made or continued because it would materially impede, delay or interfere with any material financing, offer and sale of securities, acquisition, merger, tender offer, business combination, corporate reorganization or other significant transaction involving Insmed or because such registration would require Insmed to disclose material nonpublic information that would not otherwise be required to be disclosed under applicable law and (2) Insmed has a bona fide business purpose for preserving the confidentiality of such transaction or information (a “Valid Business Reason”), (x) Insmed may postpone filing a Registration Statement (but not the preparation of the Registration Statement) relating to a Demand Registration until such Valid Business Reason no longer exists, but in no event for more than sixty (60) days after the date when the Demand Registration was requested or, if later, after the occurrence of the Valid Business Reason and (y) in case a Registration Statement has been filed relating to a Demand Registration, Insmed may postpone amending or supplementing such Registration Statement (in which case, if the Valid Business Reason no longer exists or if more than sixty (60) days have passed since such postponement, the Initiating Holders may request a new Demand Registration (which request shall not be counted as an additional Demand Registration for purposes of clause (i) above) or request the prompt amendment or supplement of such Registration Statement).  Insmed shall give written notice to all Designated Shareholders of its determination to postpone filing, amending or supplementing a Registration Statement and of the fact that the Valid Business Reason for such postponement no longer exists, in each case, promptly after the occurrence thereof.  Notwithstanding anything to the contrary contained herein, Insmed may not postpone a filing, amendment or supplement under this Section 3(a) due to a Valid Business Reason more than once in any twelve (12)-month period.  Each request for a Demand Registration by the Initiating Holders shall state the type and amount of the Registrable Securities proposed to be sold and the intended method of disposition thereof.

 

(b) Incidental or “Piggy-Back” Rights with Respect to a Demand Registration

 

Any Designated Shareholder that has not requested a registration under Section 3(a) hereof may, pursuant to this Section 3(b), offer its Registrable Securities under any Demand Registration.  Insmed shall (i) as promptly as practicable, but in no event later than five Business Days after the receipt of a request for a Demand Registration from the Initiating Holders, give written notice thereof to all of the Designated Shareholders (other than Initiating Holders which have requested a registration under Section 3(a) hereof), which notice shall specify the type and number of Registrable Securities subject to the request for Demand Registration, the names of the Initiating Holders and the intended method of disposition of such Registrable Securities, and (ii) subject to Section 3(e) hereof, include in the Registration Statement filed pursuant to the Demand Registration all of the Registrable Securities held by such Designated Shareholders from whom Insmed has received a written request for inclusion therein within five Business Days of the date on which such Designated Shareholders received the written notice referred to in clause (i) above.  Each such request by such Designated Shareholders shall specify the type and number of Registrable Securities proposed to be registered.  The failure of any Designated Shareholder to respond within such five Business Day period referred to in clause (ii) above shall be deemed to be a waiver of such Designated Shareholder’s rights under this Section 3(b) with respect to such Demand Registration.  Any Designated Shareholder may waive its rights under this Section 3(b) by giving written notice to Insmed.

 

(c) Effective Demand Registration

 

Subject to Section 3(a), Insmed shall use its reasonable best efforts (taking into account, among other things, accounting and regulatory matters) to file a Registration Statement relating to the Demand Registration and to use its reasonable best efforts to cause such Registration Statement to become effective as promptly as practicable but in no event later than one hundred twenty days after it receives a request under Section 3(a) hereof and to remain continuously effective for the lesser of (i) the period during which all Registrable Securities registered in the Demand Registration are sold or (ii) one hundred eighty (180) days; provided, however, that a registration shall not constitute a Demand Registration if (x) after such Demand Registration has become effective, such registration or the related offer, sale or distribution of Registrable Securities thereunder is interfered with by any stop order, injunction or other order or requirement of the Commission or other governmental agency or court for any reason not attributable to the Designated Shareholders and such interference is not thereafter eliminated or (y) the conditions specified in the underwriting agreement, if any, entered into in connection with such Demand Registration are not satisfied or waived as a result of an action or inaction by Insmed.

 

(d) Expenses

 

Except as provided in Section 3(g) or the last sentence of Section 7(d) hereof, Insmed shall pay all Registration Expenses in connection with a Demand Registration, whether or not such Demand Registration becomes effective.

 

(e) Underwriting Procedures

 

If the Majority Initiating Holders so elect, Insmed shall use its reasonable best efforts to cause the offering made pursuant to such Demand Registration pursuant to this Section 3 to be in the form of a firm commitment underwritten public offering and the managing underwriter or underwriters selected for such offering shall be the Approved Underwriter selected in accordance with Section 3(f) hereof.  In connection with any Demand Registration under this Section 3 involving an underwritten public offering, none of the Registrable Securities held by any Designated Shareholder making a request for inclusion of such Registrable Securities pursuant to Section 3(a) or 3(b) hereof shall be included in such underwritten public offering unless such Designated Shareholder accepts the terms of the offering as agreed upon by Insmed, the Majority Initiating Holders and the Approved Underwriter (including, without limitation, offering price, underwriting commissions or discounts and lockup agreement terms), and then only in such quantity as set forth below.  If the Approved Underwriter advises Insmed that the aggregate amount of such Registrable Securities requested to be included in such offering is sufficiently large to have a material adverse effect on the distribution or sales price of the Registrable Securities in such offering, then Insmed shall include in such Demand Registration, to the extent of the amount that the Approved Underwriter believes may be sold without causing such material adverse effect, first, such number of Registrable Securities of the Designated Shareholders that are participating in such offering pursuant to Section 3(a) or 3(b) hereof, which Registrable Securities shall be allocated pro rata among such Designated Shareholders participating in the offering, based on the number of Registrable Securities held by each such Designated Shareholder, second, any other securities of Insmed requested by any other holders thereof to be included in such registration, pro rata among such other holders based on the number of securities held by each such holder, and third, securities offered by Insmed for its own account.

 

(f) Selection of Underwriters

 

If any Demand Registration or S-3 Registration, as the case may be, of Registrable Securities is in the form of an underwritten public offering, Insmed shall select and obtain one or more investment banking firms of national reputation to act as the managing underwriter or underwriters of the offering; provided, however, that such firm or firms shall, in any case, also be approved by the Majority Initiating Holders or Majority Shelf Take-Down Shareholders, as the case may be, such approval not to be unreasonably delayed or withheld.  An investment banking firm or firms selected pursuant to this Section 3(f) shall be referred to as the “Approved Underwriter” herein.

 

(g) Withdrawal

 

The Majority Initiating Holders shall be entitled to withdraw or revoke a request for a Demand Registration without the prior written consent of Insmed if (i) such withdrawal or revocation is as a result of facts or circumstances arising after the date on which a request for a Demand Registration was made and the Majority Initiating Holders reasonably determine that participation in such registration would have a material adverse effect on the Initiating Holders or (ii) the Initiating Holders agree to pay all fees and expenses incurred by Insmed in connection with such withdrawn registration (each, a “Permitted Withdrawal”).  If a Permitted Withdrawal occurs under clause (i) above, the related Demand Registration shall be counted as a Demand Registration for purposes of Section 3(a) hereof, and if a Permitted Withdrawal occurs under clause (ii) above, the related Demand Registration shall not be counted as a Demand Registration for purposes of Section 3(a) hereof.  Any Permitted Withdrawal shall constitute and effect an automatic withdrawal by all other Initiating Holders and any other Designated Shareholder participating in such Demand Registration pursuant to the provisions of Section 3(b) hereof.

 

4. Incidental or “Piggy-Back” Registration

 

(a) Request for Incidental or “Piggy-Back” Registration

 

After May 30, 2011, if Insmed proposes to file a Registration Statement with respect to an offering of Common Stock by Insmed for its own account (other than a Registration Statement on Form S-4 or S-8) or for the account of any stockholder of Insmed other than Designated Shareholders pursuant to Sections 3 and 5 hereof, then Insmed shall give written notice (an “Incidental Registration Notice”) of such proposed filing to each of the Designated Shareholders at least thirty (30) days before the anticipated filing date, which notice shall describe the proposed registration and distribution, the proposed date of filing of such Registration Statement, any proposed managing underwriter or underwriters and a good faith estimate by Insmed of the proposed maximum offering price thereof, as such price is proposed to appear on the facing page of such Registration Statement, and offer such Designated Shareholders the opportunity to register the number of Registrable Securities that each such Designated Shareholder may request (an “Incidental Registration”).  Any such request by a Designated Shareholder must be made in writing and received by Insmed within five Business Days of the date on which the Designated Shareholder received the Incidental Registration Notice.  The failure of any Designated Shareholder to respond to an Incidental Registration Notice within ten (10) Business Days shall be deemed a waiver of such Designated Shareholder’s rights under this Section 4(a) with respect to such Incidental Registration.  Insmed shall use its reasonable best efforts to cause the managing underwriter or underwriters in the case of a proposed underwritten public offering (the “Insmed Underwriter”) to permit each Designated Shareholder who has requested in writing to participate in the Incidental Registration pursuant to this Section 4(a) to include the number of such Designated Shareholder’s Registrable Securities indicated by such Designated Shareholder in such offering on the same terms and conditions as the Common Stock of Insmed or the account of such other stockholder, as the case may be, included therein.  Any withdrawal of the Registration Statement by Insmed for any reason shall constitute and effect an automatic withdrawal of any Incidental Registration related thereto.  In connection with any Incidental Registration under this Section 4(a) involving an underwritten public offering, Insmed shall not be required to include any Registrable Securities in such underwritten public offering unless the Designated Shareholders thereof accept the terms of the underwritten public offering as agreed upon between Insmed, such other stockholders, if any, and Insmed Underwriter (including, without limitation, offering price, underwriting commissions or discounts and lock-up agreement terms), and then only in such quantity as set forth below.  If the Insmed Underwriter determines that the aggregate amount of the securities requested to be included in such offering is sufficiently large to have a material adverse effect on the distribution or sales price of the securities in such offering, then Insmed shall include in such Incidental Registration, to the extent of the amount that the Insmed Underwriter believes may be sold without causing such material adverse effect, first, (i) all of the securities to be offered for the account of Insmed, in the case of an Insmed initiated Incidental Registration or (ii) all of the securities to be offered for the account of the stockholders who have requested such Incidental Registration, in the case of a stockholder initiated Incidental Registration, second, any Registrable Securities and any other shares of Common Stock requested by holders thereof (including the Designated Shareholders) to be included in such registration (to the extent that the holders of such securities do not have priority to be included in such registration), pro rata among the Designated Shareholders and such other holders based on the number of securities held by each such holder, and third, all of the securities to be offered for the account of Insmed, in the case of an Incidental Registration initiated by any stockholder of Insmed.

 

(b) Expenses

 

Except as provided in the last sentence of Section 7(d) hereof, Insmed shall bear all Registration Expenses in connection with any Incidental Registration pursuant to this Section 4, whether or not such Incidental Registration becomes effective.

 

5. Form S-3 Registration

 

(a) Form S-3 Registration

 

If Insmed is eligible to use Form S-3 under the Securities Act in connection with a secondary public offering of its equity securities, Insmed shall register under the Securities Act on Form S-3 (an “S-3 Registration”) the sale of all of the Registrable Securities (which S-3 Registration shall be a shelf registration pursuant to Rule 415 promulgated under the Securities Act) provided herein.  Subject to the terms of this Agreement, Insmed shall use its reasonable best efforts to file a Registration Statement relating to the S-3 Registration (taking into account, among other things, accounting and regulatory matters) and to use its reasonable best efforts to cause such Registration Statement to become effective, in each case, as promptly as practicable but in no event later than the Target Filing Date.  Subject to the terms of this Agreement, if the Registration Statement for an S-3 Registration ceases to be effective after the third anniversary of its effectiveness, if Insmed is eligible to use Form S-3 under the Securities Act in connection with a secondary public offering of its equity securities, at the written request of the Majority Designated Shareholders, Insmed shall use its reasonable best efforts to file a new Registration Statement relating to the S-3 Registration (taking into account, among other things, accounting and regulatory matters) and to use its reasonable best efforts to cause such Registration Statement to become effective, in each case, as promptly as practicable but in no event later than ninety (90) days after the prior Registration Statement ceases to be effective; provided, that the Designated Shareholders request for inclusion in the new Registration Statement relating to such S-3 Registration at least $10,000,000 of Registrable Securities (calculated based upon the Market Price of the Registrable Securities on the date which the Majority Designated Shareholders make such request).  If the Majority S-3 Participating Shareholders request, and if Insmed is a Well-Known Seasoned Issuer, Insmed shall cause such S-3 Registration to be made pursuant to an Automatic Shelf Registration Statement and may omit the names of the S-3 Participating Shareholders and the amount of the Registrable Securities to be offered thereunder.  Any Registration Statement filed under this Section 5(a) shall be referred to as a “Form S-3 Shelf Registration Statement.”

 

(b) Form S-3 Underwriting Procedures

 

In an Underwritten Shelf Take-Down, the managing underwriter or underwriters selected for such offering shall be the Approved Underwriter selected in accordance with Section 3(f) hereof.  In connection with an Underwritten Shelf Take-Down, none of the Registrable Securities held by any Designated Shareholder having such Registrable Securities included pursuant to Section 5(a) hereof shall be included in such Underwritten Shelf Take-Down unless such Designated Shareholder accepts the terms of the offering as agreed upon by Insmed, the Majority Shelf Take-Down Shareholders and the Approved Underwriter (including, without limitation, offering price, underwriting commissions and discounts and lock-up agreement terms) and then only in such quantity as set forth below.  If the Approved Underwriter advises Insmed that the aggregate amount of such Registrable Securities requested to be included in such offering is sufficiently large to have a material adverse effect on the distribution or sales price of the Registrable Securities in such offering then Insmed shall include in such offering, to the extent of the amount that the Approved Underwriter believes may be sold without causing such material adverse effect, first, such number of Registrable Securities of the Designated Shareholders that are participating in such Underwritten Shelf Take-Down, which Registrable Securities shall be allocated pro rata among such Designated Shareholders participating in such Undewritten Shelf Take-Down, based on the number of Registrable Securities held by each such Designated Shareholder, second, any other securities of Insmed requested by any other holders thereof to be included in such Underwritten Shelf Take-Down and third, securities offered by Insmed for its own account.  Notwithstanding the foregoing, immediately upon determination of the price at which such Registrable Securities are to be sold in an offering in an S-3 Registration that is an Underwritten Shelf Take-Down, if such price is below the price which the Majority Shelf Take-Down Shareholders find acceptable, then such Majority Shelf Take-Down Shareholders shall then have the right, by written notice to Insmed, to withdraw their Registrable Securities from being included in such offering; provided, that such a withdrawal by such Majority Shelf Take-Down Shareholders shall constitute and effect an automatic withdrawal by all other S-3 Participating Shareholders.

 

(c) Limitations on Form S-3 Registrations

 

If the Board of Directors determines that a Valid Business Reason exists, (x) Insmed may postpone filing a Registration Statement relating to an S-3 Registration (but not the preparation of the Registration Statement) until such Valid Business Reason no longer exists, but in no event for more than sixty (60) days after the Target Filing Date or, if later, after the occurrence of the Valid Business Reason and (y) in case a Registration Statement has been filed relating to an S-3 Registration, Insmed may postpone amending or supplementing such Registration Statement (in which case, if the Valid Business Reason no longer exists or if more than sixty (60) days have passed since such postponement, the Majority S-3 Participating Shareholders may request the prompt amendment or supplement of such Registration Statement or a new S-3 Registration).  Insmed shall give written notice to all Designated Shareholders of its determination to postpone or delay amending or supplementing a Registration Statement and of the fact that the Valid Business Reason for such postponement or delay no longer exists, in each case, promptly after the occurrence thereof.  Notwithstanding anything to the contrary contained herein, Insmed may not postpone a filing or delay amending or supplementing a filing under this Section 5(c) due to a Valid Business Reason more than once in any six-month period.

 

(d) Expenses

 

Except as provided in the last sentence of Section 7(d) hereof, Insmed shall bear all Registration Expenses in connection with any S-3 Registration pursuant to this Section 5, whether or not such S-3 Registration becomes effective.

 

(e) Automatic Shelf Registration Statement

 

After the Registration Statement with respect to an S-3 Registration that is an Automatic Shelf Registration Statement becomes effective, upon written request by the S-3 Participating Shareholders, Insmed shall, as promptly as practicable after receiving such request, (i) file with the Commission a prospectus supplement naming the S-3 Participating Shareholders as selling stockholders and the amount of Registrable Securities to be offered and include, to the extent not included or incorporated by reference in the Registration Statement, any other information omitted from the Prospectus used in connection with such Registration Statement as permitted by Rule 430B promulgated under the Securities Act (including the plan of distribution and the names of any underwriters, placement agents or brokers) and (ii) pay any necessary filing fees to the Commission within the time period required.

 

(f) Shelf Take-Downs

 

(i)   Any Designated Shareholder (an “Initiating Shelf Holder”) that holds Registrable Securities included in a Form S-3 Shelf Registration Statement may initiate an offering or sale of all or part of such Registrable Securities (a “Shelf Take-Down”), in which case the provisions of this Section 5(f) shall apply.

 

(ii) If in connection with any Shelf Take-Down, the Majority Shelf Take-Down Shareholders so elect in a written request delivered to Insmed (an “Underwritten Shelf Take-Down Notice”), a Shelf Take-Down may be in the form of an underwritten public offering (an “Underwritten Shelf Take-Down”) and, subject to the limitations set forth in the proviso to Section 5(b), Insmed shall file and effect an amendment or supplement to its Form S-3 Shelf Registration Statement for such purpose as soon as practicable.   Such Majority Shelf Take-Down Shareholders shall indicate in such Underwritten Shelf Take-Down Notice whether it intends for such Underwritten Shelf Take-Down to involve a customary “road show” (including an “electronic road show”) or other substantial marketing effort by the underwriters (a “Marketed Underwritten Shelf Take-Down”).  Upon receipt of an Underwritten Shelf Take-Down Notice indicating that such Underwritten Shelf Take-Down will be a Marketed Underwritten Shelf Take-Down, Insmed shall promptly (but in any event no later than ten Business Days prior to the expected date of such Marketed Underwritten Shelf Take-Down) give written notice of such Marketed Underwritten Shelf Take-Down to all other S-3 Participating Shareholders and shall permit the participation of all such S-3 Participating Shareholders that request inclusion in such Marketed Underwritten Shelf Take-Down who respond in writing within five Business Days after the receipt of such notice of their election to participate.  The provisions of Section 5(b) shall apply with respect to the right of the Initiating Shelf Holder and any other Shelf Holder to participate in any Underwritten Shelf Take-Down.

 

(iii) If any Initiating Shelf Holder desires to effect a Shelf Take-Down that does not constitute a Marketed Underwritten Shelf Take-Down (a “Non-Marketed Underwritten Shelf Take-Down”), such Initiating Shelf Holder shall so indicate in a written request delivered to Insmed no later than two Business Days prior to the expected date of such Non-Marketed Underwritten Shelf Take-Down, which request shall include (i) the total number of Registrable Securities expected to be offered and sold in such Non-Marketed Underwritten Shelf Take-Down, (ii) the expected plan of distribution of such Non-Marketed Underwritten Shelf Take-Down and (iii) the action or actions required (including the timing thereof) in connection with such Non-Marketed Underwritten Shelf Take-Down (including the delivery of one or more stock certificates representing shares of Registrable Securities to be sold in such Non-Marketed Underwritten Shelf Take-Down), and, subject to the limitations set forth in Sections 5(a) and (b), Insmed shall file and effect an amendment or supplement to its Form S-3 Shelf Registration Statement for such purpose as soon as practicable.

 

6. Holdback Agreements

 

(a) Restrictions on Public Sale by Designated Shareholders

 

(i) To the extent requested by the Approved Underwriter or the Insmed Underwriter, as the case may be, in the case of an underwritten public offering, each Designated Shareholder (other than any Pledgee) agrees (x) not to effect any public sale or distribution of any Registrable Securities or of any securities convertible into or exchangeable or exercisable for such Registrable Securities, including a sale pursuant to Rule 144 (or any successor rule or regulation) promulgated under the Securities Act, or offer to sell, contract to sell (including, without limitation, any short sale), grant any option to purchase or enter into any hedging or similar transaction with the same economic effect as a sale of, any Registrable Securities and (y) except as otherwise consented to by Insmed, not to make any request for a Demand Registration or S-3 Registration under this Agreement, in each case, during the Specified Period following the effective date of such Registration Statement, except in each case as part of such underwritten public offering.

 

(ii) Notwithstanding anything herein to the contrary, no Pledgee shall be required to agree to any restriction on its ability to trade in any securities, including the restrictions set forth in this Section 6(a).  The Designated Shareholders hereby agree that they shall act in good faith with respect to the restrictions set forth in this Section 6(a) and shall take no action or omit to take any action with the intention of circumventing or evading the restrictions applicable to them under this Section 6(a).

 

(b) Restrictions on Public Sale by Insmed

 

Unless Insmed shall have received the prior written consent of the Majority Designated Shareholders, Insmed agrees not to (i) effect any public sale or distribution of any of its securities, or any securities convertible into or exchangeable or exercisable for such securities (except pursuant to registrations on Form S-4 or S-8), (ii) file any Registration Statements relating to the registration of securities for Insmed’s account (except pursuant to registrations on Form S-4 or S-8) or (iii) make any public announcements related to clause (i) or (ii), in each case, during the period beginning on the effective date of any Registration Statement relating to an underwritten public offering in which the Designated Shareholders of Registrable Securities are participating pursuant to Section 3 or 5 hereof and ending on the earlier of (x) the date on which all Registrable Securities registered on such Registration Statement are sold and (y) the Specified Period after the effective date of such Registration Statement (except as part of such registration).

 

7. Registration Procedures

 

(a) Obligations of Insmed

 

Whenever registration of Registrable Securities has been requested or required pursuant to Section 3, Section 4 or Section 5 hereof, Insmed shall use its reasonable best efforts to effect the registration and sale of such Registrable Securities in accordance with the intended method of distribution thereof as quickly as practicable, and in connection with any such request, Insmed shall:

 

(i) use its reasonable best efforts (taking into account, among other things, accounting and regulatory matters) to prepare and file with the Commission a Registration Statement on any form for which Insmed then qualifies or which counsel for Insmed shall deem appropriate and which form shall be available for the sale of such Registrable Securities in accordance with the intended method of distribution thereof, and use its reasonable best efforts to cause such Registration Statement to become effective; provided, however, that (x) before filing a Registration Statement or Prospectus or any amendments or supplements thereto (including, without limitation, any documents incorporated by reference therein), or before using any Free Writing Prospectus, Insmed shall provide one firm of legal counsel selected by the Designated Shareholders holding a majority of the Registrable Securities being registered in such registration (“Designated Shareholders’ Counsel”), any managing underwriter or broker/dealer participating in any disposition of such Registrable Securities pursuant to a Registration Statement and any attorney retained by any such managing underwriter or broker/dealer (each, an “Inspector” and collectively, the “Inspectors”) with an adequate and appropriate opportunity to review and comment on such Registration Statement and each Prospectus included therein (and each amendment or supplement thereto) and each Free Writing Prospectus to be filed with the Commission, subject to such documents being under Insmed’s control, and (y) Insmed shall promptly notify the Designated Shareholders’ Counsel and each seller of Registrable Securities pursuant to such Registration Statement of any stop order issued or threatened by the Commission and take all reasonable best efforts required to prevent the entry of such stop order or to remove it if entered;

 

(ii) prepare and file with the Commission such amendments and supplements to such Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective for the lesser of (x) one hundred eighty (180) days (or, in the case of an S-3 Registration, three years from the effective date of the Registration Statement if such Registration Statement is filed pursuant to Rule 415 promulgated under the Securities Act) and (y) such shorter period which will terminate when all Registrable Securities covered by such Registration Statement have been sold (or, if such Registration Statement is an Automatic Shelf Registration Statement, on the third anniversary of the date of filing of such Automatic Shelf Registration Statement); and shall comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such Registration Statement during such period in accordance with the intended methods of disposition by the sellers thereof set forth in such Registration Statement.  Notwithstanding the foregoing, Insmed shall be entitled at all reasonable times to suspend a Registration Statement that includes Registrable Securities during the pendency of any amendments required by this Section 7(a)(ii).  Such suspension or suspensions shall be effective upon transmittal of notice to an affected Designated Shareholder, in compliance with, and using the most expeditious practical means of communication permitted by Section 10(e) below.

 

(iii) furnish to each seller of Registrable Securities, prior to filing a Registration Statement relating to Registrable Securities, at least one copy of such Registration Statement as is proposed to be filed, and thereafter such number of copies of such Registration Statement, each amendment and supplement thereto (in each case including all exhibits thereto), the Prospectus included in such Registration Statement (including each preliminary Prospectus), any Prospectus filed under Rule 424 under the Securities Act and any Free Writing Prospectus as each such seller may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such seller;

 

(iv) register or qualify such Registrable Securities under such other securities or “blue sky” laws of such jurisdictions as any seller of Registrable Securities may reasonably request, and continue such registration or qualification in effect in such jurisdiction for as long as permissible pursuant to the laws of such jurisdiction, or for as long as any such seller requests or until all of such Registrable Securities are sold, whichever is shortest, and do any and all other acts and things which may be reasonably necessary or advisable to enable any such seller to consummate the disposition in such jurisdictions of the Registrable Securities owned by such seller; provided, however, that Insmed shall not be required to (x) qualify generally to do business as a foreign entity in any jurisdiction where it is not then so qualified, (y) subject itself to taxation in any such jurisdiction or (z) consent to general service of process in any such jurisdiction;

 

(v) promptly notify each seller of Registrable Securities: (A) when a Prospectus, any Prospectus supplement, any Free Writing Prospectus, a Registration Statement or a post-effective amendment to a Registration Statement has been filed with the Commission, and, with respect to a Registration Statement or any post-effective amendment, when the same has become effective; (B) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration Statement, related Prospectus or Free Writing Prospectus or for additional information; (C) of the issuance by the Commission or any other governmental authority of any stop order suspending the effectiveness of a Registration Statement relating to Registrable Securities or of any order suspending or preventing the use of any related prospectus or the initiation or threatening of any proceedings for that purpose; (D) of the receipt by Insmed of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction or the initiation or threatening of any proceedings for such purpose; (E) of the existence of any fact or happening of any event (including the passage of time) of which Insmed has knowledge which makes any statement of a material fact in such Registration Statement, related Prospectus or Free Writing Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue or which would require the making of any changes in the Registration Statement, Prospectus or Free Writing Prospectus in order that, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the case of such Prospectus or Free Writing Prospectus, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and (F) determination by counsel of Insmed that a post-effective amendment to a Registration Statement relating to Registrable Securities is advisable;

 

(vi) use its reasonable best efforts to, upon the occurrence of any event contemplated by Section 7(a)(v)(E) hereof or, subject to Sections 3(a) and 5(c) hereof, the existence of a Valid Business Reason, prepare a supplement or amendment to such Registration Statement, related Prospectus or Free Writing Prospectus and furnish to each seller of Registrable Securities a reasonable number of copies of such supplement to, or amendment of, such Registration Statement, Prospectus or Free Writing Prospectus as may be necessary so that, after delivery to the purchasers of such Registrable Securities, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the case of such Prospectus or Free Writing Prospectus, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading;

 

(vii) enter into and perform customary agreements (including an underwriting agreement in customary form with the Approved Underwriter or Insmed Underwriter, if any, selected as provided in Section 3, Section 4 or Section 5 hereof, as the case may be) and take such other reasonable best actions as are reasonably required in order to facilitate the disposition of such Registrable Securities, including causing its officers to participate in “road shows” and other information meetings organized by the Approved Underwriter or Insmed Underwriter;

 

(viii) make available at reasonable times for inspection by any Inspector all pertinent financial and other records, pertinent corporate documents and properties of Insmed and its subsidiaries (collectively, the “Records”) as shall be reasonably necessary to enable them to exercise their due diligence responsibility, and cause Insmed’s and its subsidiaries’ officers, directors and employees, and the independent public accountants of Insmed, to supply all information reasonably requested by any such Inspector in connection with such Registration Statement.  Records that Insmed determines, in good faith, to be confidential and which it notifies the Inspectors are confidential shall not be disclosed by the Inspectors (and the Inspectors shall confirm their agreement in writing in advance to Insmed if Insmed shall so request) unless (x) the disclosure of such Records is necessary, in Insmed’s judgment, to avoid or correct a misstatement or omission in the Registration Statement, (y) the release of such Records is ordered pursuant to a subpoena or other order from a court of competent jurisdiction after exhaustion of all appeals therefrom or (z) the information in such Records was known to the Inspectors on a non-confidential basis prior to its disclosure by Insmed or has been made generally available to the public.  Each seller of Registrable Securities agrees that it shall, upon learning that disclosure of such Records is sought in a court of competent jurisdiction, promptly give notice to Insmed and allow Insmed, at Insmed’s expense, to undertake appropriate action to prevent disclosure of the Records deemed confidential.  In the event that Insmed is unsuccessful in preventing the disclosure of such Records, such seller agrees that it shall furnish only such portion of those Records that it is advised by counsel is legally required and shall exercise all reasonable efforts to obtain reliable assurance that confidential treatment will be accorded to those Records;

 

(ix) if such sale is pursuant to an underwritten offering, obtain a “cold comfort” letter dated the effective date of the Registration Statement and the date of the closing under the underwriting agreement from Insmed’s independent public accountants in customary form and covering such matters of the type customarily covered by “cold comfort” letters as the managing underwriter reasonably requests;

 

(x) if such sale is pursuant to an underwritten offering, furnish, at the request of any seller of Registrable Securities on the date such securities are delivered to the underwriters for sale pursuant to such registration, an opinion, dated such date, of counsel representing Insmed for the purposes of such registration, addressed to the underwriters, covering such legal matters with respect to the registration in respect of which such opinion is being given as the underwriters may reasonably request and are customarily included in such opinions;

 

(xi) comply with all applicable rules and regulations of the Commission, and make available to its security holders, as soon as reasonably practicable but no later than fifteen months after the effective date of the Registration Statement, an earnings statement covering a period of twelve months beginning after the effective date of the Registration Statement, in a manner which satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 promulgated under the Securities Act;

 

(xii) cause as of the effective date of the Registration Statement, any shares of Common Stock included in the Registration Statement to be listed on each securities exchange on which the Common Stock is then listed, including but not limited to the Nasdaq Capital Market, provided that the applicable listing requirements are satisfied;

 

(xiii) keep Designated Shareholders’ Counsel reasonably advised in writing as to the initiation and progress of any registration hereunder; provided, that Insmed shall provide Designated Shareholders’ Counsel with all correspondence with the Commission in connection with any Registration Statement filed hereunder to the extent that such Registration Statement has not been declared effective on or prior to the date required hereunder;

 

(xiv) cooperate with each seller of Registrable Securities and each underwriter participating in the disposition of such Registrable Securities and their respective counsel in connection with any filings required to be made with FINRA;

 

(xv) cause the Registrable Securities covered by such Registration Statement to be registered with or approved by such other governmental agencies or authorities, as may be reasonably necessary by virtue of the business and operations of Insmed to enable the seller or sellers of Registrable Securities to consummate the disposition of such Registrable Securities;

 

(xvi) within the deadlines specified by the Securities Act and the rules promulgated thereunder, make all required filings of all Prospectuses and Free Writing Prospectuses with the Commission;

 

(xvii) within the deadlines specified by the Securities Act and the rules promulgated thereunder, make all required filing fee payments in respect of any Registration Statement or Prospectus used under this Agreement (and any offering covered thereby); and

 

(xviii) take all other steps reasonably necessary and advisable to effect the registration of the Registrable Securities contemplated hereby and reasonably cooperate with the holders of such Registrable Securities to facilitate the disposition of such Registrable Securities pursuant thereto.

 

(b) Seller Requirements

 

In connection with any offering under any Registration Statement under this Agreement, each Designated Shareholder (i) shall promptly furnish to Insmed in writing such information with respect to such Designated Shareholder and the intended method of disposition of its Registrable Securities as Insmed may reasonably request or as may be required by law or regulations for use in connection with any related Registration Statement or Prospectus (or amendment or supplement thereto) and all information required to be disclosed in order to make the information previously furnished to Insmed by such Designated Shareholder not contain a material misstatement of fact or necessary to cause such Registration Statement or Prospectus (or amendment or supplement thereto) not to omit a material fact with respect to such Designated Shareholder necessary in order to make the statements therein not misleading; (ii) shall comply with the Securities Act and the Exchange Act and all applicable state securities laws and comply with all applicable regulations in connection with the registration and the disposition of the Registrable Securities; and (iii) shall not use any Free Writing Prospectus without the prior written consent of Insmed.  If any seller of Registrable Securities fails to provide such information required to be included in such Registration Statement by applicable securities laws or otherwise necessary or desirable in connection with the disposition of such Registrable Securities in a timely manner after written request therefor, Insmed may exclude such seller’s Registrable Securities from a registration under Sections 3, 4 or 5 hereof.

 

(c) Notice to Discontinue

 

Each Designated Shareholder agrees that, upon receipt of any notice from Insmed of the happening of any event of the kind described in Section 7(a)(v)(E) hereof or, subject to Section 3(a) and 5(c) hereof, the existence of Valid Business Reason, such Designated Shareholder shall forthwith discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until such Designated Shareholder’s receipt of the copies of the supplemented or amended Prospectus or Free Writing Prospectus contemplated by Section 7(a)(vi) hereof (or if no supplemental or amended prospectus or Free Writing Prospectus is required, upon confirmation from Insmed that use of the Prospectus or Free Writing Prospectus is once again permitted) and, if so directed by Insmed, such Designated Shareholder shall deliver to Insmed (at Insmed’s expense) all copies, other than permanent file copies then in such Designated Shareholder’s possession, of the Prospectus or Free Writing Prospectus covering such Registrable Securities which is current at the time of receipt of such notice.  If Insmed shall give any such notice, Insmed shall extend the period during which such Registration Statement shall be maintained effective pursuant to this Agreement  by the number of days during the period from and including the date of the giving of such notice and including the date when sellers of such Registrable Securities under such Registration Statement shall have received the copies of the supplemented or amended Prospectus or Free Writing Prospectus contemplated by and meeting the requirements of Section 7(a)(v) hereof (or if no supplemental or amended prospectus or Free Writing Prospectus is required, upon confirmation from Insmed that use of the Prospectus or Free Writing Prospectus is once again permitted); provided, that, no single suspension under this Section 7(c) shall exceed forty-five (45) days in any one hundred and eight (180) day period and in no event shall more than one suspension event exceed, in the aggregate, sixty (60) days in any twelve (12) month period.

 

(d) Registration Expenses

 

Except as otherwise provided herein, including but not limited to the last sentence of this Section 7(d), Insmed shall pay all expenses arising from or incident to its performance of, or compliance with, this Agreement, including, without limitation (i) all expenses, including filing fees, in connection with the preparation and filing of the Registration Statement, preliminary prospectus or final prospectus and amendments and supplements thereto, (ii) Commission, stock exchange and FINRA registration (including any counsel retained in connection with FINRA registration) and filing fees, (iii) transfer agents’ and registrars’ fees and expenses, (iv) all fees and expenses incurred in complying with state securities or “blue sky” laws (including reasonable fees, charges and disbursements of counsel to any underwriter incurred in connection with “blue sky” qualifications of the Registrable Securities as may be set forth in any underwriting agreement), (v) all printing, messenger and delivery expenses, (vi) the fees, charges and expenses of counsel to Insmed and of its independent registered public accounting firm and any other accounting fees, charges and expenses incurred by Insmed (including, without limitation, any expenses arising from any “cold comfort” letters or any special audits incident to or required by any registration or qualification), (vii) the reasonable fees, charges and expenses of the Designated Shareholders’ Counsel (including without limitation the reasonable fees, charges and expenses incurred in connection with any amendments to a Registration Statement) and (viii) any liability insurance or other premiums for insurance obtained in connection with any Demand Registration or piggy-back registration thereon, Incidental Registration or S-3 Registration pursuant to the terms of this Agreement, regardless of whether such Registration Statement is declared effective.  All of the expenses described in the preceding sentence of this Section 7(d) are referred to herein as “Registration Expenses.”  The Designated Shareholders of Registrable Securities sold pursuant to a Registration Statement shall bear the expense of any broker’s commission or underwriter’s discount or commission relating to the registration and sale of such Designated Shareholders’ Registrable Securities and shall bear the fees and expenses of their own counsel (other than the Designated Shareholders’ Counsel).

 

8. Indemnification; Contribution

 

(a) Indemnification by Insmed

 

Insmed agrees to indemnify and hold harmless each Designated Shareholder, its general or limited partners, directors, officers, Affiliates, stockholders, members, employees, trustees and each Person who controls (within the meaning of Section 15 of the Securities Act) such Designated Shareholder from and against any and all losses, claims, damages, liabilities and expenses, or any action or proceeding in respect thereof (including, but not limited to, reasonable costs and expenses of legal counsel arising from any investigation, action or proceeding in respect of any of the foregoing) (each, a “Liability” and collectively, “Liabilities”), arising out of or based upon (a) any untrue, or allegedly untrue, statement of a material fact contained in the Disclosure Package, the Registration Statement, the Prospectus, any Free Writing Prospectus or in any amendment or supplement thereto; and (b) the omission or alleged omission to state in the Disclosure Package, the Registration Statement, the Prospectus, any Free Writing Prospectus or in any amendment or supplement thereto any material fact required to be stated therein or necessary to make the statements therein not misleading under the circumstances such statements were made; provided, however, that Insmed shall not be held liable in any such case to the extent that any such Liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission contained in such Disclosure Package, Registration Statement, Prospectus, Free Writing Prospectus or such amendment or supplement thereto in reliance upon and in conformity with written information concerning such Designated Shareholder furnished to Insmed by or on behalf of such Designated Shareholder expressly for use therein, including, without limitation, the information furnished to Insmed pursuant to Sections 7(b) and 8(b) hereof.  Insmed shall also provide customary indemnities to any underwriters of the Registrable Securities, their officers, directors and employees and each Person who controls such underwriters (within the meaning of Section 15 of the Securities Act) to the same extent as provided above with respect to the indemnification of the Designated Shareholders of Registrable Securities.

 

(b) Indemnification by Designated Shareholders

 

In connection with any offering in which a Designated Shareholder is participating pursuant to Section 3, 4 or 5 hereof, such Designated Shareholder agrees severally to indemnify and hold harmless Insmed, the other Designated Shareholders, any underwriter retained by Insmed and each Person who controls Insmed, the other Designated Shareholders or such underwriter (within the meaning of Section 15 of the Securities Act) to the same extent as the foregoing indemnity from Insmed to the Designated Shareholders (including indemnification of their respective partners, directors, officers, Affiliates, stockholders, members, employees, trustees and Controlling Persons), but only to the extent that Liabilities arise out of or are based upon a statement or alleged statement or an omission or alleged omission that was made in reliance upon and in conformity with information with respect to such Designated Shareholder furnished in writing to Insmed by or on behalf of such Designated Shareholder expressly for use in such Disclosure Package, Registration Statement, Prospectus, Free Writing Prospectus or such amendment or supplement thereto, including, without limitation, the information furnished to Insmed pursuant to Section 7(b) hereof; provided, however, that the total amount to be indemnified by such Designated Shareholder pursuant to this Section 8(b) shall be limited to the net proceeds received by such Designated Shareholders in the offering to which such Disclosure Package, Registration Statement, Prospectus, Free Writing Prospectus or such amendment or supplement thereto relates.

 

(c) Conduct of Indemnification Proceedings

 

Any Person entitled to indemnification or contribution hereunder (the “Indemnified Party”) agrees to give prompt written notice to the indemnifying party (the “Indemnifying Party”) after the receipt by the Indemnified Party of any written notice of the commencement of any action, suit, proceeding or investigation or threat thereof made in writing for which the Indemnified Party intends to claim indemnification or contribution pursuant to this Agreement; provided, however, that the failure to so notify the Indemnifying Party shall not relieve the Indemnifying Party of any Liability that it may have to the Indemnified Party hereunder (except to the extent that the Indemnifying Party is materially prejudiced or otherwise forfeits substantive rights or defenses by reason of such failure).  If notice of commencement of any such action is given to the Indemnifying Party as above provided, the Indemnifying Party shall be entitled to participate in and, to the extent it may wish, jointly with any other Indemnifying Party similarly notified, to assume the defense of such action at its own expense, with counsel chosen by it and reasonably satisfactory to such Indemnified Party.  Each Indemnified Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the reasonable and documented out-of-pocket fees and expenses of such counsel shall be paid by the Indemnified Party unless (i) the Indemnifying Party agrees to pay the same, (ii) the Indemnifying Party fails to assume the defense of such action with counsel reasonably satisfactory to the Indemnified Party or (iii) the named parties to any such action (including any impleaded parties) include both the Indemnifying Party and the Indemnified Party and such parties have been advised by such counsel that either (x) representation of such Indemnified Party and the Indemnifying Party by the same counsel would be inappropriate under applicable standards of professional conduct or (y) there may be one or more legal defenses available to the Indemnified Party which are different from or additional to those available to the Indemnifying Party.  In any of such cases, the Indemnifying Party shall not have the right to assume the defense of such action on behalf of such Indemnified Party, it being understood, however, that the Indemnifying Party shall not be liable for the reasonable and documented out-of-pocket fees and expenses of more than one separate firm of attorneys (in addition to any local counsel) for all Indemnified Parties and all such reasonable and documented out-of-pocket fees and expenses shall be reimbursed as incurred.  No Indemnifying Party shall be liable for any settlement entered into without its written consent, which consent shall not be unreasonably withheld.  No Indemnifying Party shall, without the consent of such Indemnified Party, which consent shall not be unreasonably withheld, effect any settlement of any pending or threatened proceeding in respect of which such Indemnified Party is a party and indemnity has been sought hereunder by such Indemnified Party, unless such settlement includes an unconditional release of such Indemnified Party from all liability for claims that are the subject matter of such proceeding.

 

(d) Contribution

 

If the indemnification provided for in this Section 8 from the Indemnifying Party is unavailable to an Indemnified Party hereunder or insufficient to hold harmless an Indemnified Party in respect of any Liabilities referred to herein, then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Liabilities in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions which resulted in such Liabilities, as well as any other relevant equitable considerations.  The relative faults of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, has been made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action.  The amount paid or payable by a party as a result of the Liabilities referred to above shall be deemed to include, subject to the limitations set forth in Sections 8(a), 8(b) and 8(c) hereof, any reasonable and documented out-of-pocket legal or other fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding; provided, that the total amount to be contributed by any Designated Shareholder shall be limited to the net proceeds (after deducting the underwriters’ discounts and commissions) received by such Designated Shareholder in the offering.

 

The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 8(d) were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding paragraph.  No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution or indemnification from any Person who was not guilty of such fraudulent misrepresentation.

 

9. Rule 144

 

Insmed covenants that it shall take such action as may be required from time to time to enable such Designated Shareholder to sell Registrable Securities without registration under the Securities Act within the limitation of the exemptions provided by (i) Rule 144 under the Securities Act, as such rule may be amended from time to time, or Regulation S under the Securities Act or(ii) any similar rules or regulations hereafter adopted by the Commission.  Insmed shall, upon the request of any Designated Shareholder, deliver to such Designated Shareholder a written statement as to whether it has complied with such requirements.

 

10. Miscellaneous

 

(a) Stock Splits, etc.

 

  The provisions of this Agreement shall be appropriately adjusted for any stock dividends, splits, reverse splits, combinations recapitalizations and the like occurring after the date hereof.

 

(b) Inconsistent Agreements

 

Insmed hereby represents and warrants that it has not previously entered into any agreement granting registration rights to any Person with respect to any securities of Insmed.  So long as any Registrable Securities or shares of Preferred Stock remain outstanding, Insmed shall not enter into any agreement with respect to its securities that is inconsistent with the rights granted to the Designated Shareholders in this Agreement or grant any additional registration rights to any Person or with respect to any securities that are not Registrable Securities which rights are senior or on par with the rights granted in this Agreement without the prior written consent of the Designated Shareholders holding greater than 62.5% of the Registrable Securities then held by the Designated Shareholders.

 

(c) Remedies

 

The Designated Shareholders, in addition to being entitled to exercise all rights granted by law, including recovery of damages, shall be entitled to specific performance of their rights under this Agreement.  Insmed agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Agreement and hereby agrees to waive in any action for specific performance the defense that a remedy at law would be adequate.

 

(d) Amendments and Waivers

 

Except as otherwise provided herein, the provisions of this Agreement may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given unless consented to in writing by Insmed and the Majority Designated Shareholders; provided, however, that no amendment, modification, supplement, waiver or consent to depart from the provisions hereof shall be effective if such amendment, modification, supplement, waiver or consent to depart from the provisions hereof materially and adversely affects the substantive rights or obligations of one Designated Shareholder, or group of Designated Shareholders, without a similar and proportionate effect on the substantive rights or obligations of all Designated Shareholders, unless each such disproportionately affected Designated Shareholder consents in writing thereto.

 

(e) Notices

 

All notices, demands and other communications provided for or permitted hereunder shall be made in writing and shall be made by registered or certified first-class mail, return receipt requested, telecopy, electronic transmission, courier service or personal delivery:

 

(i) If to Insmed:

 

Insmed Incorporated

8720 Stony Point Parkway, Suite 200

Richmond, Virginia, 23235

Telecopy:  (434) 977-7920

Attention:  Mr. W. McIlwaine Thompson, Secretary

 

with a copy to:

 

Greenberg Traurig LLP

 

200 Park Avenue

 

New York, New York 10166

 

Telecopy: (212) 805-5539

 

Attention:  Joseph A. Herz

 

	
(ii)  

	
If to any Designated Shareholder, at its address as it appears in the books and records of Insmed.

 

All such notices, demands and other communications shall be deemed to have been duly given, and received by the recipient, when delivered by hand, if personally delivered; when delivered by courier, if delivered by commercial courier service, but in any event two Business Days after being sent by Insmed; two Business Days after being deposited in the mail, postage prepaid, if mailed; and when receipt is acknowledged, if telecopied, or electronically transmitted, but in any event one Business Day after being sent by Insmed.  Any party may by notice given in accordance with this Section 10(e) designate another address or Person for receipt of notices hereunder.

 

(f) Permitted Assignees; Third Party Beneficiaries

 

This Agreement shall inure to the benefit of and be binding upon the permitted assignees of the parties hereto as provided in Section 2(d) hereof.  Except as provided in Section 8 hereof, no Person other than the parties hereto and their permitted assignees is intended to be a beneficiary of this Agreement.

 

(g) Aggregation of Stock

 

All shares of Registrable Securities held or acquired by Affiliated entities or Persons or entities or Persons under common management or control shall be aggregated together for the purpose of determining the availability of any rights under this Agreement.

 

(h) Counterparts

 

This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts (and by facsimile or portable document format (pdf) transmission), each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

 

(i) Headings

 

The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

 

(j) GOVERNING LAW

 

THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF.

 

(k) Jurisdiction

 

Any action or proceeding relating to this Agreement or the enforcement of any provision of this Agreement may be brought or otherwise commenced in any state or federal court located in the Borough of Manhattan in the State of New York.  Each party to this Agreement: (i) expressly and irrevocably consents and submits to the exclusive jurisdiction of each state and federal court located in the Borough of Manhattan in the State of New York (and each appellate court located in the State of New York) in connection with any such action or proceeding; (ii) agrees that each state and federal court located in the Borough of Manhattan in the State of New York shall be deemed to be a convenient forum; and (iii) agrees not to assert (by way of motion, as a defense or otherwise), in any such action or proceeding commenced in any state or federal court located in the Borough of Manhattan in the State of New York, any claim that such party is not subject personally to the jurisdiction of such court, that such action or proceeding has been brought in an inconvenient forum, that the venue of such proceeding is improper or that this Agreement or the subject matter of this Agreement may not be enforced in or by such court.

 

(l) WAIVER OF JURY TRIAL

 

EACH PARTY, ON BEHALF OF ITSELF AND ITS RESPECTIVE SUCCESSORS AND ASSIGNS, HEREBY IRREVOCABLY WAIVES ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION BASED UPON, OR ARISING OUT OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

(m) Severability

 

If any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable in any respect for any reason, the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions hereof shall not be in any way impaired.

 

(n) Rules of Construction

 

Unless the context otherwise requires, references to sections or subsections refer to sections or subsections of this Agreement.  Terms defined in the singular have a comparable meaning when used in the plural, and vice versa.

 

(o) Entire Agreement

 

This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto with respect to the subject matter contained herein.  There are no restrictions, promises, representations, warranties or undertakings with respect to the subject matter contained herein, other than those set forth or referred to herein.  This Agreement supersedes all prior agreements and understandings among the parties with respect to such subject matter.

 

(p) Further Assurances

 

Each of the parties shall execute such documents and perform such further acts as may be reasonably required or desirable to carry out or to perform the provisions of this Agreement.

 

(q) Other Agreements

 

Nothing contained in this Agreement shall be deemed to be a waiver of, or release from, any obligations any party hereto may have under, or any restrictions on the transfer of Registrable Securities or other securities of Insmed imposed by, any other agreement.

 

  

  

  

IN WITNESS WHEREOF, the undersigned have executed, or have caused to be executed, this Registration Rights Agreement on the date first written above.

 

 

INSMED INCORPORATED

 

 

By: /s/ Kevin P. Tully                                                                           

 

 

Name:  Kevin P. Tully

 

 

Title:    Executive Vice President and Chief Financial Officer

 

 

  

  

 

	
  

	
Shareholders

 

PROSPECT VENTURES PARTNERS III, L.P.

 

By: Prospect Management Co. III, L.L.C.

Its: General Partner

 

 

	
  

	
By:

	
/s/ Alex Barkas

	 

 

	
  

	
Name:  Alex Barkas

 

	
  

	
Title:    Managing Member

 

 

 

QUAKER BIOVENTURES II, L.P.

 

By: QUAKER BIOVENTURES CAPITAL II, L.P.

Its: General Partner

	
  

	
By: QUAKER BIOVENTURES CAPITAL II, LLC

Its: General Partner

By: __/s/ Richard Kollender__________________

Name: Richard Kollender

Title:   Vice President

 

 

BESSEMER VENTURE PARTNERS VII INSTITUTIONAL L.P.

 

	
  

	
By: Deer VII & Co. L.P.

	
  

	
Its:  General Partner

By: Deer VII & Co. Ltd.

Its: General Partner

 

	
  

	
By:

	
/s/ J.Edmond Colloton

 

	
  

	
Name:  J. Edmond Colloton

 

	
  

	
Title:   Director

 

 

 

BESSEMER VENTURE PARTNERS VII, L.P.

 

	
  

	
By: Deer VII & Co. L.P.

	
  

	
Its:  General Partner

By: Deer VII & Co. Ltd.

Its: General Partner

 

	
  

	
By:

	
/s/ J.Edmond Colloton

 

	
  

	
Name:  J. Edmond Colloton

 

	
  

	
Title:   Director

 

 

 

CHRISTOPHER GABRIELI

 

By: /s/ Christopher Gabrieli                                                                           

 

 

SETH ORLOW

 

By: /s/ Seth Orlow                                                                           

 

 

TVM V LIFE SCIENCE VENTURES GmbH & Co. KG

	
  

	
By: /s/ Mark G. Cipriano   /s/ David Poltack

Name: Mark G. Cipriano   David Poltack

Title:  Managing Limited Partners

TVM IV GmbH & Co. KG

	
  

	
By: /s/ Mark G. Cipriano   /s/ David Poltack

Name: Mark G. Cipriano   David Poltack

Title:  Authorized Signatories

  

EASTON HUNT CAPITAL PARTNERS, L.P.

	
  

	
By: EHC GP, L.P.

	
  

	
Its:  General Partner

By: EHC, Inc.

Its: General Partner

 

	
  

	
By:

	
/s/ Richard P. Schneider

	 

 

	
  

	
Name:  Richard P. Schneider

 

	
  

	
Title:    Vice President & Secretary

 

 

 

BEACON BIOVENTURES LIMITED PARTNERSHIP

	
  

	
By:  Beacon Bioventures Advisors, L.P.

	
  

	
Its:  General Partner

By: Fidelity Biosciences Corp.

Its: General Partner

 

	
  

	
By:

	
/s/ Richard W. Fedorowich, Jr.

	 

 

	
  

	
Name:  Richard P. Fedorowich, Jr.

 

	
  

	
Title:    Chief Financial Officer

 

 

 

BEACON BIOVENTURES PRINCIPALS LIMITED PARTNERSHIP

	
  

	
By:  Beacon Bioventures Advisors, L.P.

	
  

	
Its:   General Partner

By: Fidelity Biosciences Corp.

Its: General Partner

 

	
  

	
By:

	
/s/ Richard W. Fedorowich, Jr.

	 

 

	
  

	
Name:  Richard P. Fedorowich, Jr.

 

	
  

	
Title:    Chief Financial Officer

 

 

	
  

	
COOPERATIEVE AAC LS U.A.

 

	
 

	 By: /s/ M.A. van Osch   /s/ G.J. Mulder

Name: M.A. van Osch G.J. Mulder

Title:  Partners

  

 

  

 

[Name and Address of Transferee]

 

Insmed Incorporated

 

8720 Stony Point Parkway

 

Richmond, VA  23235

 

[Name and Address of Transferor]

 

________, 20__

 

Ladies and Gentlemen:

 

Reference is made to the Registration Rights Agreement, dated as of ______ __, 2010 (the “Registration Rights Agreement”), by and among Insmed Incorporated, a Virginia corporation, and the certain stockholders named therein.  All capitalized terms used herein but not otherwise defined shall have the meanings given to them in the Registration Rights Agreement.

 

In connection with the transfer by [Name of Transferor] of Registrable Securities with associated registration rights under the Registration Rights Agreement to [Name of Transferee] as transferee (the “Transferee”), the Transferee hereby agrees to be bound as a Designated Shareholder by the provisions of the Registration Rights Agreement as provided under Section 2(d)(i) thereto. 

 

This consent shall be governed by Delaware law.

 

 

Yours sincerely,

 

 

[Name of Transferee]

 

 

	
  

	
By:

	 	 

 

 

	
  

	
Name:

 

 

	
  

	
Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]